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ABSTRACT
Adenovirus (AdV) infection is ubiquitous in the human population and causes acute
infection in the respiratory and gastrointestinal tracts. In addition to lytic infections in epithelial
cells, AdV can persist in a latent form in mucosal lymphocytes, and nearly 80% of children contain
viral DNA in the lymphocytes of their tonsils and adenoids. Reactivation of latent AdV is thought
to be the source of deadly viremia in pediatric transplant patients. Adenovirus latency and
reactivation in lymphocytes is not well-studied, though immune cell activation has been reported
to promote productive infection from latency. In lymphocytes, programs of gene expression during
both resting and activated states have been shown to be regulated in part by chromatin remodelers
and co-repressors, including Class I and II histone deacetylases (HDACs), Class III HDACs
(sirtuins), and the C-terminal Binding Protein Family (CtBPs). Because the adenovirus genome is

chromatinized through rapid association with cellular histones upon entry into the host cell
nucleus, viral gene expression is potentially regulated by these same cellular chromatin-modifying
mechanisms and responsive to immunoactivation of the host lymphocyte. In this doctoral work,
we show that enzymatic activity of Class I HDACs and sirtuins, but not Class II HDACs, contribute
to the repression of viral early and late genes during persistent infection. We also show that
modulation of cellular NAD+/NADH can de-repress adenovirus gene expression in persistentlyinfected lymphocytes. In contrast, disrupting the NAD-dependent CtBP repressor complex
interaction with PxDLS-containing binding partners paradoxically alters AdV gene expression.

INDEX WORDS: Adenovirus latency, Adenovirus persistent infection, Histone deacetylase,
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HISTONE DEACETYLASE-LINKED REPRESSION AND METABOLICALLY-LINKED
DEREPRESSION OF ADENOVIRUS PERSISTENT INFECTION OF LYMPHOCYTES

by

MEGAN LOUISE DICKHERBER

A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy
in the College of Arts and Sciences
Georgia State University
2019

Copyright by
Megan Louise Dickherber
2019

HISTONE DEACETYLASE-LINKED REPRESSION AND METABOLICALLY-LINKED
DEREPRESSION OF ADENOVIRUS PERSISTENT INFECTION OF LYMPHOCYTES

by

MEGAN LOUISE DICKHERBER

Committee Chair: Charlese Garnett-Benson

Committee:

Margo Brinton
Casonya Johnson

Electronic Version Approved:

Office of Graduate Studies
College of Arts and Sciences
Georgia State University
December 2019

iv

DEDICATION
I dedicate my doctoral work to my husband, Tony, and my two children, Marcus and Cela.

To my husband, Tony – You have been by my side through successes and failures,
believing in me even when I did not. You have always been in the trenches with me, willing to
hear a practice presentation or be a proof-reader or discuss my project, no matter what time of day
or night. We share the drive to challenge ourselves and to give back to the world some of our
blessings. You are the love of my life.

To my children, Marcus and Cela – You are the sunshine in my every day and inspire me
to be my best self. I am lucky you are mine.

ii

ACKNOWLEDGEMENTS
I would like to thank my advisor, Dr. Charlie Benson, for taking me under her wing and
guiding me through my doctoral work. I have not met a teacher or mentor as committed to her
students as she has been. She viewed every interaction as an opportunity to grow and to help us
reach the next level of accomplishment. Her passion for science and love of learning, and her
fearlessness towards new challenges have been truly inspiring.
I would like to thank Dr. Margo Brinton for her guidance and patient feedback over the
last several years and multiple classes I took from her. She was always available to talk through
challenges or ideas and give expert insight into how to tackle them. She had high standards for
students in her classes and gave the support to help them get there. Her unabashed love of science
(and especially RNA) made learning with her fun.
I would also like to thank Dr. Casonya Johnson for serving on my committee and her
continued support for navigating the doctoral program and thinking “big-picture” about what my
long-term goals are. Her way of getting right to the heart of the matter in a kind and supportive
manner have helped motivate my work and career goals.

iii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS .........................................................................................................II
LIST OF TABLES ................................................................................................................... VIII
LIST OF FIGURES .................................................................................................................... IX
LIST OF ABBREVIATIONS .................................................................................................... XI
1

INTRODUCTION ............................................................................................................. 1
1.1

Human Adenoviruses ................................................................................................... 1

1.2

Viral Structure, Life Cycle, and Tropism .................................................................. 3

1.2.1 Lytic Infection ........................................................................................................... 3
1.2.2 Persistent Infection ................................................................................................... 4
1.3

Chromatin Structure of AdV Genome ....................................................................... 6

1.3.1 AdV Genome is Episomal ......................................................................................... 7
1.3.2 AdV Genome Organization and Overview of Transcriptional Program ................ 7
1.3.3 Chromatin Structure during Lytic Infection............................................................ 8
1.3.4 Chromatin Structure of AdV Vectors ..................................................................... 11
1.3.5 Chromatin Structure during Persistent Infection.................................................. 12
1.4

Transcriptional Regulation of Viral Gene Expression ............................................ 12

1.4.1 Viral E1A-289R ....................................................................................................... 13
1.4.2 Histone Acetyltransferases (HATs): p300 and Tip60 ............................................ 17
1.4.3 Class I and II HDACs ............................................................................................. 17

iv

1.4.4 Class III HDACs – Sirtuins .................................................................................... 18
1.4.5 Co-repressive C-terminal Binding Proteins (CtBPs) ............................................. 19
1.5

Overarching Hypothesis ............................................................................................. 20

References ................................................................................................................................ 21
2

NAD-LINKED MECHANISMS OF GENE DE-REPRESSION AND A NOVEL
ROLE FOR CTBP IN PERSISTENT ADENOVIRUS INFECTION OF
LYMPHOCYTES ............................................................................................................ 33
2.1

Abstract ....................................................................................................................... 33

2.2

Background ................................................................................................................. 34

2.3

Materials and Methods............................................................................................... 38

2.4

Results .......................................................................................................................... 44

2.4.1 Viral transcription in persistently-infected lymphocytes is repressed compared to
lytically-infected cells but relative amounts across viral transcripts are similar .. 44
2.4.2 Cellular activation of infected lymphocyte cell lines upregulates viral gene
expression ................................................................................................................ 47
2.4.3 Infection with adenovirus can reduce the NAD+/NADH ratio and
PMA/ionomycin stimulation shifts this ratio in lymphocytic cell lines ................ 48
2.4.4 Direct modulation of the NAD+/NADH ratio can upregulate viral gene
expression in persistently-infected cells ................................................................. 51
2.4.5 Differential expression of CtBP homologs between lymphocytes and epithelial
cells .......................................................................................................................... 52

v

2.4.6 Inhibition of CtBP-E1A interaction upregulates E1A 13S expression in T
lymphocyte cell lines ............................................................................................... 54
2.5

Discussion .................................................................................................................... 58

2.6

Conclusion ................................................................................................................... 67

References ................................................................................................................................ 67
3

CONTRIBUTIONS OF CLASS I, II, AND III HDACS TO VIRAL GENE
REPRESSION DURING ADENOVIRUS PERSISTENT INFECTION ................... 75
3.1

Background ................................................................................................................. 75

3.2

Materials and Methods............................................................................................... 79

3.3

Results .......................................................................................................................... 84

3.3.1 Class I HDACs are ubiquitously expressed, but Class II HDACs are
differentially expressed across cell-line models of infection ................................. 84
3.3.2 Enzymatic activity of Class I HDACs, but not Class II, is involved in repression
of AdV genes in persistently-infected lymphocyte cell lines. ................................. 86
3.3.3 Activating Class III HDACs (sirtuins) with resveratrol upregulates E1A
expression. ............................................................................................................... 88
3.3.4 Inhibiting SIRT1 and SIRT2 with sirtinol upregulates E3 and hexon in
persistently-infected cell lines. ................................................................................ 89
3.3.5 Long-term sirtuin inhibition with nicotinamide does not prevent establishment of
persistent infection. ................................................................................................. 91
3.4

Discussion .................................................................................................................... 94

vi

3.5

Conclusion ................................................................................................................... 96

References ................................................................................................................................ 96
4

LIMITATIONS OF CURRENT APPROACHES FOR THE STUDY OF
ADENOVIRUS PERSISTENT INFECTION ............................................................. 101
4.1

Background ............................................................................................................... 101

4.2

Materials and Methods............................................................................................. 102

4.3

Results: Part A - Determining the Frequency of AdV-Infected Cells in a
Persistently-Infected Cell Culture ........................................................................... 105

4.3.1 Ad5GFP establishes persistent infection in BJAB and Jurkat cell lines, but GFP
expression is repressed alongside AdV genes ...................................................... 107
4.3.2 Repressed GFP and hexon genes respond to histone deacetylase (HDAC)
inhibition and phorbol 12-myristate 13-acetate (PMA) ionomycin (Iono)
treatment in persistently-infected Jurkat cells ..................................................... 109
4.4

Conclusions: Part A - Determining the Frequency of AdV-Infected Cells in a
Persistently-Infected Cell Culture ........................................................................... 111

4.5

Results: Part B - Detection of Viral Proteins in Low Abundance ....................... 112

4.5.1 E1A proteins are not detectable in persistently infected KE37 and BJAB cell lines
due to non-specific binding of anti-E1A antibody ............................................... 113
4.5.2 E2 DNA-binding protein is detectable in persistently-infected T cell lines ........ 115
4.6

Conclusions: Part B - Detection of Viral Proteins in Low Abundance ............... 116

4.7

Future Work.............................................................................................................. 117

vii

References .............................................................................................................................. 117
5

CONCLUSIONS AND FUTURE STUDIES............................................................... 120
5.1

Discussion .................................................................................................................. 120

References .............................................................................................................................. 126
APPENDICES ........................................................................................................................... 130
Cell viability and density with different treatment drugs ................................................. 130
Appendix A – Nicotinamide treatment ............................................................................... 130
Appendix B – Trichostatin A (TSA) treatment .................................................................. 131
Appendix C – Tacedinaline treatment ................................................................................ 132
Appendix D – TMP195 treatment ....................................................................................... 133
Appendix E – NSC95397 treatment .................................................................................... 134
Appendix F – Tubacin treatment ........................................................................................ 135
Appendix G – Resveratrol treatment .................................................................................. 136
Appendix H – Sirtinol treatment ......................................................................................... 137

viii

LIST OF TABLES
Table 1-1. Major protein products and their functions from AdV transcription units. ................... 9
Table 1-2. Transcription factor binding sites and regulatory elements in E1A-responsive viral
promoters. .......................................................................................................................... 16

ix

LIST OF FIGURES
Figure 1-1. Structure of an Adenovirus Particle. ............................................................................. 3
Figure 1-2. Comparison of events and tropism of lytic and persistent infection. ........................... 6
Figure 1-3. Genomic organization of AdV-C5............................................................................... 8
Figure 1-4. Adenovirus E1A major isoforms. ............................................................................... 13
Figure 1-5. E1A-289R transactivation of AdV early genes. ......................................................... 14
Figure 1-6. Conserved regions of E1A-289R and their cellular binding partners......................... 15
Figure 1-7. Overarching Hypothesis ............................................................................................. 21
Figure 2-1.Characterization of viral genome quantities and transcriptional repression in
persistently-infected lymphocytes. .................................................................................... 45
Figure 2-2.Cell stimulation with PMA and Ionomycin upregulates viral gene expression in
infected lymphocytic cell lines. ......................................................................................... 49
Figure 2-3. PMA and ionomycin treatment increases NAD+/NADH ratio in lymphocyte cell
lines.................................................................................................................................... 50
Figure 2-4. Viral gene expression is responsive to the NAD+/NADH ratio. ................................ 53
Figure 2-5. Epithelial cells and lymphocytic cells differ in CtBP2 expression............................. 55
Figure 2-6. CtBP-binding inhibitor, NSC95397, differentially impacts AdV gene expression
across lymphocytic and epithelial cell lines. ..................................................................... 56
Figure 3-1. Regulation of HDAC function during infection with DNA viruses. .......................... 77
Figure 3-2. Class I and II HDAC protein levels in cell line models of AdV infection. ................ 85
Figure 3-3. Inhibitors of Class I and II HDACs. ........................................................................... 86
Figure 3-4. Treatment with Class I, but not Class IIa, HDAC inhibitors increases viral gene
expression in persistently-infected cell lines. .................................................................... 87

x

Figure 3-5. Treatment with HDAC6 inhibitor (Class IIb) does not alter viral gene expression. .. 88
Figure 3-6. Activating sirtuins with resveratrol upregulates E1A and down-regulates hexon in
persistently-infected lymphocytic cell lines. ..................................................................... 90
Figure 3-7. Inhibition of SIRT1 and SIRT2 with sirtinol upregulates viral gene expression. ...... 90
Figure 3-8. Long-term sirtuin inhibition with NAM does not prevent establishment of persistent
infection. ............................................................................................................................ 93
Figure 4-1. Percent of cells expressing GFP and hexon during acute infection with Ad5GFP in
lymphocyte cell lines. ...................................................................................................... 108
Figure 4-2. Treatment with HDAC inhibitor TSA increases number of cells expressing GFP
reporter gene in persistently-infected Jurkat cells. .......................................................... 110
Figure 4-3. Treatment with PMA/Ionomycin increases number of cells expressing GFP and
hexon in persistently-infected Jurkat cells. ..................................................................... 110
Figure 4-4. Immunoblot for E1A in persistently-infected lymphocytes. .................................... 114
Figure 4-5. E2 DNA-binding protein is detectable in persistently-infected T cells. ................... 116

xi

LIST OF ABBREVIATIONS

ACTB
ADP
AdV
ALL
APC
BSA
CAR
ChIP
CMV
CR
CtBP
DBF
DBP
DDR
Dpi
DMEM
DNMT
EBV
EIF1
FISH
FCS
FITC
GAPDH
GFP
HAT
HDAC
HDACi
HPV
HRP
HPRT1
HPV
HSCT
HSV
iBJAB
iKE37
Iono
ITR
KSHV
LCR
MEF2
MIEP
MLP
MOI

b-actin
Adenovirus Death Protein
Adenovirus
Acute Lymphoblastic Leukemia
Allophycocyanin
Bovine Serum Albumin
Coxsackie and Adenovirus Receptor
Chromatin immunoprecipitation
Cytomegalovirus
Conserved Region
C-terminal Binding Protein
DNA binding factor
AdV DNA-binding protein
DNA damage response
Days post infection
Dulbecco’s modified Eagle medium
DNA methyltransferase
Epstein-Barr Virus
Eukaryotic translation initiation factor 1
Fluorescence in situ hybridization
Fetal Calf Serum
Fluorescein Isothiocyanate
Glyceraldehyde-3-phosphate Dehydrogenase
Green fluorescent protein
Histone acetyltransferase
Histone Deacetylase
HDAC inhibitor
human papilloma virus
Horseradish Peroxidase
Hypoxanthine Phosphoribosyltransferase 1
Human papilloma virus
Hematopoietic Stem Cell Transplant
Herpes simplex virus
Infected BJAB cells
Infected KE37 cells
Ionomycin
Inverted terminal repeat
Kaposi’s sarcoma-associated herpesvirus
Long coding region
myocyte enhancer binding factor 2
CMV major immediate early gene promoter
AdV major late promoter
Multiplicity of Infection

xii

NAD+
NADH
NAM
PARP
PE
PFU
PKR
PBS
PMA
PRC
RCA
RPMI
RT-qPCR
RV
SDS-PAGE
SF
shRNA
siRNA
TAF-1b
TBST
Tip60
TCC
TET
TLR
TPL
TSA
TSS
VA RNA

Nicotinamide adenine dinucleotide
Nicotinamide adenine dinucleotide (NAD) + hydrogen (H)
Nicotinamide
Poly(ADP-ribose) polymerase
Phycoerythrin
Plaque-forming unit
Protein kinase R
Phosphate-buffered saline
Phorbol 12-myristate 13-acetate
Polycomb repressive complex
Rolling circle amplification
Roswell Park Memorial Institute
Reverse transcription – quantitative polymerase chain reaction
Resveratrol
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
Serum-free
Short hairpin RNA
Silencing RNA
Template activating factor 1b
Tris-buffered Saline with Tween
Tat-interacting protein 60
Tethered chromosome capture
Ten-eleven translocation family proteins
Toll-like receptor
Tripartite leader
Trichostatin A
Transcription start site
Virus-associated RNA

1

1 INTRODUCTION
This doctoral thesis focuses on mechanisms of transcriptional regulation of adenovirus
(AdV) persistent infection in lymphocytes. In this introductory chapter, a brief overview of the
human adenoviruses will be given with rationale for the study of AdV Species C in connection
with persistent infection. An overview of the sequential steps occurring in the lytic infection of
epithelial cells will then be compared to what is known for persistent infection described in cell
lines models and primary lymphocytes. Because our studies have focused on mechanisms of gene
expression regulation, a review of what is known of viral chromatin structure in lytic and persistent
infection and in the context of adenoviral vector transgene delivery will be given. This chapter will
conclude with a review of known mechanisms of transcriptional regulation of the adenovirus
genome, with rationale for the overarching hypothesis for this work.
1.1

Human Adenoviruses
Human adenoviruses were discovered in 1953 by Rowe et al. as the cytopathogenic

agent present in cultured adenoid tissues (1) and independently by Hilleman et al. as a cause of an
acute respiratory disease outbreak among military personnel (2). Since then, the viruses of the
family Adenoviridae have been found in all major classes of vertebrates, with the genus
Mastadenovirus containing mammalian adenoviruses including the seven species (A-G) found in
human hosts (3). Currently there are more than 85 types of human AdV that have been identified
through serotyping and genomic analysis (4-6). Human AdV infections cause a variety of different
diseases including conjunctivitis (A, B, E), gastroenteritis (A, F, G), and respiratory disease (B, C,
E) (3).
Infections with Species C (types 1 and 2) were among the AdVs most reported in a 2017
survey in the U.S. (7), and these along with Species C type 5 are most commonly associated with
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symptomatic respiratory infections (8). AdV-C infections predominantly occur in very young
children and are a major cause of respiratory disease in pediatric patients (9-12). In a study of
extracted tonsils or adenoids, approximately 80% of patients under age 19 contained AdV-C (types
1, 2, 5, and 6) DNA in lymphocytes of those tissues, most in a non-replicating state (10). In
addition, AdV-C are responsible for more than half of adenovirus infections and severe disease in
immunocompromised patients (6,11). Pediatric patients receiving hematopoietic stem cell
transplants (HSCT) are at significant risk for developing disseminated AdV infection, with AdVrelated post-transplantation mortality between 3.2 and 6.0%, or approximately 100 children per
year in the U.S. (13,14). These infections can result from de novo exposure to the virus, but
reactivation of latent adenovirus from the patient’s own tissues is the predominant cause for the
most severely immunocompromised patients (14). The mechanisms allowing the virus to persist
and the conditions inducing reactivation of the virus are almost entirely unknown. This gap in
knowledge has proven to be a critical barrier to preventing AdV-related disease in transplant
recipients.
As AdV-C is the predominant species associated with the latent or persistent infection
of mucosal tissues of the tonsils, adenoids, and gastrointestinal tract (10,15), the mechanisms
governing the persistent AdV-C infection in lymphocytes are the focus of this work. Our study
will be the first work to investigate and describe how cellular transcriptional regulators are
involved in maintenance of persistent adenovirus infection in lymphocytes. Understanding the
mechanisms for adenoviral persistence may provide novel targets for therapies to prevent
reactivation and disseminated adenoviral infection in pediatric HSCT recipients.
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1.2

Viral Structure, Life Cycle, and Tropism
AdVs are 90nm, non-enveloped viruses with 36kB linear, double-stranded DNA genomes

(3). The viral DNA is condensed into the viral particles by basic viral protein µ and packaged by
major core protein VII (16) (Figure 1-1). The capsid of the virus consists largely of a hexon protein
icosahedral shell with penton base proteins attached to protruding fiber proteins at the vertices (16)
(Figure 1-1). No host-cell proteins have been found to be associated with the viral particles (3).

Figure 1-1. Structure of an Adenovirus Particle.
Adapted from (16).
1.2.1

Lytic Infection

Epithelial cells are the primary target for AdV, and adsorption of the virus occurs when the
fiber protein attaches to the cellular protein coxsackie-adenovirus receptor (CAR) on the
membrane of the host cell. A secondary attachment via the RGD-motif in the penton base protein
to an avb3/5 integrin triggers clathrin-mediated endocytosis and the initial stages of disassembly of
the virus (16-19). Following release from the endosomes, the partially uncoated virus is transported
by microtubules to the nuclear pore (3). The viral genome, bound only to core protein VII, enters
the host cell nucleus where it is quickly chromatinized through association with cellular histones
(20).
Upon expression of viral early genes and virally associated (va) RNAs I and II, the cellular
antiviral defenses are blocked, and cellular gene expression and metabolism are dramatically
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altered to generate metabolic precursors and to drive the cell into S-phase (21,22). Following
replication of the viral genome, the late stage of infection begins with inhibition of cellular protein
translation and production of viral structural proteins. Viral particles assemble in the nucleus, and
the host cell is lysed to release thousands of viral progeny (Figure 1-2) (3,22).
1.2.2

Persistent Infection

Despite the some-what ironic fact that AdVs were discovered through persistent infection
of adenoids (1), the steps leading to the establishment of persistent AdV infection and mechanisms
of reactivation are currently almost entirely unknown. Early epidemiological studies showed that
AdV could be detected intermittently in patient fecal samples for months to years after resolution
of symptoms, indicating the presence of some viral reservoir in the host (23). As mentioned above,
it is now understood that the persistent adenovirus infection occurs in lymphocytes, and
predominantly T cells, of the tonsils, adenoids, and GI tract, with the majority of viral genomes
present in a non-replicating state (10,15).
Unlike infection of epithelial cells, species C adenoviruses infect lymphoid cells with
very different and less-studied infection kinetics. Infection of these cells begins with attachment
to the avb3/5 integrins alone, as most hematopoietic cells do not express CAR (18,24,25). While no
studies have reported on the mechanism of entry in lymphocytes, internalization may be governed
by different mechanisms than in epithelial cells (26), and other mechanisms such as caveolae- and
macropinocytosis-mediated endocytosis of adenovirus particles have been reported in various cell
types when CAR is not the primary receptor (27,28). The next steps of uncoating and transport of
the genome to the nucleus have also not been studied in lymphocytes, but unusually low expression
of viral proteins has been reported in T cell lines in which the quantities of internalized virus
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appeared normal, indicating that steps of the early life cycle in lymphocytes may deviate from
those in epithelial cells as early as post-internalization (25).
Persistent infection of lymphocytes typically does not progress to lysis but rather to a nonlytic, “smoldering” infection in which replicating virus is rare (10,13,29). Immunoactivation of
infected primary lymphocytes has been shown to induce production of infectious virus, showing
that persistence and reactivation may be closely tied to the active state of the lymphocyte (10). In
order to circumvent the challenges of obtaining naturally-infected primary lymphocytes from
patient samples to study, lymphocytic cell-line models of persistent infection have been developed
which harbor viral DNA for months in culture (13,29). These models of persistent infection also
contain low levels of replicating virus, albeit at slightly higher levels than infected primary cells
(13,29), and release low amounts of virus detectable through extraction of DNA from culture
supernatants or application of supernatants onto permissive cell lines ((13) and our unpublished
results). Viability of these persistently-infected cell lines remains unaffected (13,29), indicating
either very few cells are lysing to release the viral particles, or an as-of-yet unidentified mechanism
for egress is occurring (Figure 1-2).
The persistent infection in these lymphocytic cell-line models has been shown to be
regulated, in part, by as-of-yet uncharacterized transcriptional controls not detectable in lytic
infection of epithelial cells (see Section 1.3.2 - AdV Genome Organization and Overview of
Transcriptional Program below for more detail). Murali et al. (2014) determined that the early
gene E3-Adenovirus Death Protein (ADP), which is critical for cell lysis, was repressed both
transcriptionally and post-transcriptionally in cells which maintain the persistent infection (30).
Krzywkowski et al. (2017) showed that in a persistently-infected B cell line very few individual
cells expressed quantities of immediate early gene E1A mRNA or late gene mRNA comparable to
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lytically-infected HeLa cells, even in cells with large amounts of viral DNA (31). Furuse et al.
(2013) determined vaRNAs I and II were expressed in comparable amounts between persistentlyinfected B cells and lytically-infected epithelial cells, but in different relative proportions (32).
These few studies suggest a specific program of repression is needed to maintain the persistent
infection, but further work is needed for more complete characterization.

Epithelial Cell
CAR

1

Attachment
and Entry

8
2

Lymphocyte

5

Clathrin-Mediated
Endocytosis

αVβ3/5
integrins

Lysis

Translation

?

7
4
3

Microtubule Transport
and Nuclear Entry

Attachment
and Entry

Intermittent Viral Release:
“Smoldering” Infection

Assembly

Transcription
(Host DdRP)

6

Replication
(Viral DdDP)

Lytic Infection

Non-lytic, persistent infection

Figure 1-2. Comparison of events and tropism of lytic and persistent infection.

1.3

Chromatin Structure of AdV Genome
Despite the large body of work describing the impact of adenovirus infection on cellular

chromatin, the role of chromatin in regulation of expression from the viral genome itself has been
less well-studied. The following sections will begin with an overview of the organization of the
viral genome, then document what has been reported on chromatin structure and transcriptional
regulation of viral gene expression in the context of lytic and persistent infections. Additionally,
regulation of transgene expression from adenoviral vectors will be discussed.
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1.3.1

AdV Genome is Episomal

Unlike the genomes of other DNA viruses which integrate into the host cell DNA (33-36),
adenovirus genomes, both wild-type and vector DNA, remain episomal except for extremely rare
instances (29,37-40). The mechanisms which prevent integration have not been identified, but this
characteristic of adenoviral DNA has promoted its use as a viral vector for transgene delivery (40).
Avoiding integration may be an evolutionary advantage for the virus, as integration of foreign
DNA triggers de novo methylation and gene silencing as part of an ancient cellular antiviral
defense (41-43). In vitro methylation of the integrated E1A promoter in HEK293 cells showed
reduced expression of E1A (44), but whether this is biologically relevant has not been determined
as no DNA methylation has been reported for the episomal adenovirus genome (45).
1.3.2

AdV Genome Organization and Overview of Transcriptional Program

The program of viral transcription in lytic infection is well-documented and is primarily
orchestrated through coordination by the E1A proteins. Historically, E1A has been reported the
first transcript expressed from the viral genome, which is alternatively spliced into two principle
variants, 13S and 12S, giving rise to the 289R and 243R proteins, respectively. Through a recent
study tracking viral transcription in normal lung fibroblasts, it is now understood that non-coding
vaRNAs I and II, which inhibit the dsRNA-sensor protein kinase R (PKR), are first expressed,
followed quickly by expression of E1A and E4 (21). The viral early genes, E1B, E2, and E3 are
next expressed which prepare the cell for viral DNA replication by blocking apoptosis, producing
the viral polymerase and essential replication proteins, and tamping down the host-cell immune
response, respectively (46). Following mass production of viral DNA, the late genes are expressed
which largely encode structural and packaging proteins (3). The double-stranded AdV DNA
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genome and main transcription units are shown in Figure 1-3. The major proteins from the
transcription units and their functions are shown in Table 1-1.

IX"
E1A"E1B"
packaging(

VA I, II

5"

L2"

L1"

MLP"

10"

15"

L3"

20"

25"

Gene/
Transcription
Unit

L5"

L4"
E3"

30"

35"

First early - E1A

ITR"

ITR"
IVa2"

E2A"

Early – E3

E4"

E2B"

Late – L3

!

Figure 1-3. Genomic organization of AdV-C5.
The linear double-stranded DNA genome is depicted as a thin line, 5’ to 3’, with the
inverted terminal repeats (ITR) at each end: lengths are marked in kbps. Transcription units are
shown relative to their position and orientation. Early genes (gray bars): E1A, E1B, E2A/B, E3,
and E4. Intermediate genes (orange bars): IX and Iva2. Late genes (green bars): L1-L5, produced
from the major late promoter (MLP). Open rectangles denote introns. Late genes (L1-L5) produced
from the MLP all contain the tripartite leader (TPL) at their 5’ ends. Modified from (47) and (48).
1.3.3

Chromatin Structure during Lytic Infection

While viral DNA interacts with several viral core proteins in the formation of infectious
particles (Figure 1-1), only protein VII remains associated with the viral genome from packaged
state in the viral capsid to the host cell nucleus (66). The interaction between VII and the viral
DNA serves multiple purposes. Protein VII is a core basic protein that was originally believed to
be essential for compacting the viral genome into the capsid (67). Recent work using viruses
lacking the late VII gene showed protein VII was not essential for encapsidation, but played a more
important role in pressurizing the core and genome release (68). Upon entry of the viral genome
into the nucleus, VII monomers are spaced across the DNA similarly to histones across cellular
DNA, a structure that protects the viral DNA from activating the DNA damage response (69).
Protein VII from the incoming viral particle remains associated with the viral chromatin
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Table 1-1. Major protein products and their functions from AdV transcription units.
** denotes genes falling within the early gene region, but expressed at intermediate time
points. References for all proteins from each gene as indicated.
Early
Gene
E1A

Protein
E1A-289R
E1A-243R

E1B

19K
55K
IX**

E2

Iva2**
12.5K

(57),(58)
Unknown

6.7K
gp19K
ADP
RID-!
RID-b
E4

Activate early
genes
Induce cell cycle
(49)
Inhibit apoptosis
Inhibit p53, Ub
pathway
Capsid stability
(51),(52),(52)
DNA replication
Primes DNA
polymerase
Viral DNA
polymerase
Packaging, ATPase

DBP
pTP
pol

E3

Function

Orf1
Orf2
Orf3
Orf4
Orf4-34K
Orf6
Orf6/7

Inhibit apoptosis
MHC escape
Cell lysis/egress
¯ TNF, Fas,
TRAIL
¯ TNF, Fas,
TRAIL
(46), (30)
Unknown
Unknown
¯ host translation,
chromatin remodel
Splicing viral RNA
Packaging
¯ host translation,
Ub pathway
mRNA export,
transcription
(63),(64),(52),(48)

Late
Gene
L1

L2

Protein
52/55K

Packaging

pIIIa

Packaging
(50)
Capsid/attachment
DNA condensation

penton
pVII
pV

pVI

Secure DNA to
capsid
DNA condensation
(53),(54),(55),(56)
Endosome lysis

hexon

Capsid

protease

Maturation of
structural proteins
(50),(59),(60)
¯ translation shutoff
Packaging
Splicing, packaging
Hexon stabilization
(61),(62),(58)

pX (µ)
L3

L4

100K
22K
33K
pVIII

L5

Function

fiber

Attachment
(53)
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throughout the early phase of infection and is also important for E1A transactivation of early genes
(70).
The viral DNA/protein VII-chromatin structure that enters the nucleus must be quickly
remodeled to allow for efficient transcription of viral genes (71,72). Some protein VII is lost to
accommodate incorporation of cellular histones into the viral chromatin, and replicationindependent variant H3.3 and other core histones become localized throughout most promoter and
protein-coding regions (73,74). Although sites of high levels of protein VII binding on the viral
DNA correlate with gene repression (75,76), low levels of VII can enhance transcription, likely
through chromatin remodeling by interaction with template-activating factor 1𝛽 (TAF-1𝛽) and
nuclear phosphoprotein pp32 (members of the SET nucleosome assembly complex and inhibitor
of histone acetyltransferases [INHAT] complex, respectively) (70,72,73,77). Because increases in
acetylation of H3 can be detected as viral promoters become active, the remodeled viral chromatin
structure appears to be similar to cellular chromatin, subjecting it to regulation by the cellular
machinery (20).
Recent work has shown that interactions between the host and viral chromatin may also be
important to the program of viral gene expression. Studies using Hi-C analysis and tethered
chromosome conformation capture (TCC) to detect positioning of the viral chromatin show that
AdV DNA interacts predominately with the transcription start sites (TSSs) and enhancers of highly
active cellular chromatin (78,79). The viral genome associates with genes that are upregulated
during the course of infection, suggesting that the temporal changes in cellular gene expression
that occur may be linked with sequential expression of viral genes (79). Besides colocalization of
viral DNA and active cellular DNA, some additional interactions between the viral and host cell
chromatin were surprisingly found to be enriched at regions high in heterchromatic histone marker
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H3K27me (78). This histone marker is usually associated with repression mediated by the
Polycomb repressive complex (PRC) (80). Interestingly, the PRC complex plays a role in
regulation of latency of other DNA viruses, but whether or not PRC-based repression is involved
in adenovirus lytic or persistent infection has not been determined (81).
1.3.4

Chromatin Structure of AdV Vectors

The AdV DNA backbone is commonly used as a vehicle for gene-therapy and oncolysis
because of the extensive knowledge available about the lytic life cycle and genomic elements and
the relatively low safety risk (82). However, it is clear that suboptimal, cell type-dependent
conditions are a common challenge that must be overcome to effectively use AdVs as a delivery
mechanism. In fact, in cells that are not the primary wild-type adenoviral targets, AdV vectors
lose long-term transgene expression, mirroring some aspects of the persistent infection in
lymphocytes (83). Mechanisms that have been reported for repression of gene expression in these
systems may be important to consider in understanding the full repertoire of regulators involved
in directing the fate of the viral genome for wild-type viruses.
Like wild-type viral genomes of lytic infection, AdV vectors also are associated with
protein VII and cellular histones early in infection (84,85). This association with histones has been
shown to be important for establishing the needed chromatin structure for transgene expression
(85). However, even in the absence of all functional viral proteins, over time, transgene expression
from adenovirus vectors can be diminished through remodeling of the vector chromatin induced
by innate immune responses to the presence of the foreign DNA. Histone deacetylase inhibitors
(HDACi) can upregulate expression of transgenes delivered in vectors of several different viral
backgrounds, showing that non-specific hypoacetylation may be a mechanism of defense (86).
Suzuki et al. (2010) showed that TLR (Toll-like Receptor)-MyD88 signaling played a role in
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reduced expression of a transgene through a decrease in the active chromatin mark H3K9Ac
relative to the heterchromatic mark H3K9me2 (85,87), but future work is needed to identify the
details of the pathway and the enzymes involved.
1.3.5

Chromatin Structure during Persistent Infection

The chromatin structure of the viral genome in persistent infection is largely unstudied.
Unlike AdV-vector DNA, which often has viral genes mutated or excised, wild-type genomes with
fully intact viral genes establish persistent infection (10). The normal progression of viral gene
expression is delayed in all lymphocyte cell-line models of infection relative to infection in
epithelial cells (29), but whether this is a result of suboptimal chromatin structure has not been
studied. Considering that both genomes of lytic infection and viral vectors associate with cellular
histones (20), and that viral transcripts can be detected in persistently infected cells (10,31,32), the
in-coming viral chromatin/VII structure is likely remodeled to include cellular histones at least to
some degree. We also recently reported that AdV gene expression in persistent infections is
responsive to treatment with HDAC inhibitor trichostatin A (TSA) (Wilms et al., submitted)
further supporting a role for histones and their modification in the chromatin structure. In a recent
study using a padlock probe-based rolling-circle amplification (RCA) to evaluate concurrent AdV
DNA and mRNAs in single epithelial or lymphocytic cells, viral DNA could not be detected in
lymphocytes expressing low amounts of viral mRNA (31). This was interpreted to be a result of
protein VII interference with probe binding (31), and suggests that at least some lymphocytes
contained viral genomes which lacked proper chromatin remodeling for gene expression.
1.4

Transcriptional Regulation of Viral Gene Expression
In additional to the chromatin structure itself, a second level of regulation of viral gene

expression involves activities of cellular and viral proteins in chromatin modification and
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recruitment of transcriptional complexes to promoters of the viral genes. This section will begin
by describing the activity of the best-known transcriptional regulator of AdV gene expression, the
viral E1A-289R protein. Then key cellular enzymes and proteins that have been found to play a
role in regulation of transcription of viral genes in lytic infections and expression of AdV vector
transgenes will be discussed. This section will conclude with the statement of hypothesis for this
dissertation, concerning transcriptional regulation of viral gene expression in persistent infection
in lymphocytes.
1.4.1

Viral E1A-289R

The AdV E1A-289 protein, the larger of the two E1A isoforms (Figure 1-4), is the singlemost important protein in transcriptional regulation of the viral genome owing to its function of
transactivating the full repertoire of early genes (88). E1A-289R has no intrinsic DNA-binding
capacity, but through interaction with cellular transcription factors recruits the basal transcriptional
machinery and regulatory complexes to the early gene promoters (90). Essential to the

Figure 1-4. Adenovirus E1A major isoforms.
289R (translated from a 13S mRNA transcript) and 243R (translated from a 12S mRNA
transcript). CR: regions of E1A that are conserved across many adenovirus serotypes. CR3 is
unique to E1A-289R. Figure modified from (89).

transactivational function of E1A-289R is the interaction between CR3 and the MED23/Mediator
complex (91), a 30-unit transcriptional co-activator involved in many aspects of transcriptional
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regulation including chromatin remodeling and mRNA processing (92). Mediator is thought to
establish enhancer-promoter loops, and also is important for transcription initiation (92). Figure
1-5 depicts the E1A-289R/Mediator-regulated transactivation of the AdV early genes.

Transcription
Mediator
E1A Complex

DBF

E1A

Adenovirus Genome

E1B

E3

E2

E4

Figure 1-5. E1A-289R transactivation of AdV early genes.
The solid black line represents the viral genome (not drawn to scale), and the relative
locations of the viral early genes are shown. The first viral protein produced is E1A-289R, which
then auto-activates viral gene E1A (solid gray line). Similar E1A-containing complexes then move
to promoters of and activate viral early genes E4, E3, E1B, and E2 (dashed gray lines) (93). DBF:
any of several cellular DNA-binding factors.
While the CR3 region of E1A-289R recruits the mediator complex, the activity of this
complex has the potential to be further modified through the multitude of interactions E1A-289R
has with additional cellular proteins (49). Figure 1-6 shows many of the E1A-289R binding
partners, including transcription factors, histone acetyltransferases, co-repressors, transcriptional
machinery, and chromatin remodelers (modified from (90)). Binding sites for the transcription
factors that interact with E1A-289R, and many others, can be found in the promoters of the early
genes. Table 1-2 lists the transcriptional regulatory elements in each of the responsive viral
promoters, and the degree to which E1A-289R upregulates expression.
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CR4

Figure 1-6. Conserved regions of E1A-289R and their cellular binding partners.
Modified from (90).

In a very interesting new finding, E1A-289R transactivation of early genes E1B, E2 and
E3 was surprisingly found to be regulated in part by the interaction between E1A-289R and the
E4orf3 protein (109). E4orf3 functions largely to silence the stress response induced by viral
infection through the non-specific induction of heterochromatin formation, inadvertently silencing
viral genomes as well (110). Soriano et al. (2019) found the interaction between E1A and E4orf3
serves to fine-tune transactivation of the early genes: E1A counteracted the induction of
heterochromatin formation on the viral genome induced by E4orf3, and E4orf3 interacted with
E1A to increase occupancy of E1A and transactivational complexes at the early gene promoters.
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Table 1-2. Transcription factor binding sites and regulatory elements in E1A-responsive
viral promoters.
Adenovirus Promoter
E1A
Self upregulates 4-fold (88)

Transcription
Factor/Regulatory
Element
TATA Box
ATF

OCT1
E2F
E1A-F (ETV4)

SP1

E1B

E2-Early
E1A upregulates 10-fold
(100)

E3
Upregulated 30-fold by
E1A (102)

PMA-responsive
element
TATA-box
Sp1 (GC Box)
Sites I, II, III, IV

(94)
(94)

(94)
(94)
(94)

(94)
(95)
(96)
(97,98)
(99)

Atypical TATA-box
Atypical TBP

-30 to -25
-29 to -23

(88)
(101)

E2F

(101)

ATF

-45 to -36
-67 to -60
-76 to -69

TATA box
NF-1

-33 to -7
-183 to -154

(46)
(103)

NF-kB

-155 to -137
-134 to -113
-68 to -44
-103 to -81

(104)

(103)
(47)

TATA-Box
USF

-25
-50
-140
-53 to -47
-146 to –141
-167 to -161
-33 to -22
-63

CP1

-76

(108)

TATA
ATF
E4F1

Major Late Promoter
E1A induces 10-30-fold
upregulation (88)

Reference(s)

-30 to -23
-49 to-38
-358 to -127

ATF
AP-1

E4
100-fold increase by E1A
(106)

Position
Relative to
TSS (bps)
-21 to -38
-36 to -83
-91 to -99
-338 to -319
-414 to -391
-450 to -428
-197 to - 181
-293 to -221
-273 to -257
-304 to -289
-346 to -334
-394 to -375
-420 to -391
-447 to -442
-237 to -47

(101)

(103,105)
(103)

(107)
(88)
(108)
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1.4.2

Histone Acetyltransferases (HATs): p300 and Tip60

Histone acetyltransferase activity of p300, recruited through interaction with E1A-289R,
has recently been shown to be critical to the chromatin remodeling at AdV early gene promoters
(111). p300-induced increases in active marks H3K18ac and H3K27ac were seen at promoters for
E2, E3, and E4. Interestingly, an increase in these active marks was also noted for the E1A
promoter, suggesting a role for chromatin structure in regulation of this gene, despite speculation
that chromatinization was less relevant for this promoter (112). p300-dependent acetylation had
different effects on transcription at each viral promoter; initiation of transcription was dependent
on acetylation at the E2 promoter, but post-initiation steps were affected at the E3 and E4
promoters.
Tip60 (also known as KAT5), originally isolated and named as a cellular HIV-Tat
interacting protein, is a MYST family lysine acetyltranferase which acts as a transcriptional
regulator (113). Despite the known association between histone acetylation and active gene
expression, Tip60 appears to act in a repressive role in the AdV transcriptional program. In a study
by Gupta et al. (2013), Tip60 knock-down released repression of all AdV early genes, with a 3- to
4-fold increase in E1A expression, but had no impact on the major late promoter (MLP) (hexon
and fiber) (75). Further, Tip60 was found enriched at the TSS along with AdV protein VII and
unexpectedly, increased H4Ac at repressed E1A promoters. These findings together show that
carefully-regulated histone acetylation is important for optimal expression of AdV genes.
1.4.3

Class I and II HDACs

Despite the importance of HATs in AdV transcriptional regulation, little has been reported
about the role for their enzymatic counterparts, the histone deacetylases (HDACs). Perhaps this is
due, in part, to the rapid progression of the lytic infection where regulation of activation of viral
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genes might be more relevant. For long-term persistent infections or retention of AdV vectors,
HDACs may have a larger impact on gene expression.
Silencing of transduced genes through the chromatinization of the AdV DNA vector
backbone is a common challenge facing AdV-based oncolytic viral therapies (85). While HDAC
inhibitors (HDACi) have been reported to increase the efficiency of oncolytic viral therapy through
the increased expression of viral receptors on the cell surface (114), HDACi also have been
reported to increase expression of genes delivered in the AdV vector (115,116). Various Class I
and II HDACi have been used successfully to upregulate transgene expression in numerous cell
types and lines from a range of host species, including primary bovine or rat muscle cells (117),
human thyroid carcinoma cell lines (116), mouse neuroblastoma cells, HeLa cells, human
neuroblastoma cells, primary human dendritic cells, keratinocytes, and primary rat astrocytes (86),
and rat neurons (118). The broad diversity of vector constructs and the wide array of cellular
backgrounds in which Class I and II HDACi increase gene expression suggest HDACs act in a
non-specific manner to silence foreign DNA.
We have recently reported that HDACs play a role in persistent infection with intact viral
genomes as well; TSA upregulates transcription of several viral genes in persistently-infected
lymphocytes (Wilms et al., manuscript submitted). The work in this dissertation provides
additional insight for the involvement of Class I and II HDACs in persistent AdV infection, and
shows that activity is targeted to specific viral genes (Chapter 3).
1.4.4

Class III HDACs – Sirtuins

Sirtuins (SIRT1-7), also called Class III HDACs, are a family of nicotinamide adenine
dinucleotide (NAD+)-dependent histone deacetylases with a variety of other enzymatic activities
in the cell including ADP ribosylation, desuccinylation, and demalonylation (119). Sirtuins
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function in many aspects of essential cellular processes such as chromatin remodeling and gene
expression, apoptosis, and DNA repair (120). The NAD+-dependence of sirtuins also links function
to the metabolic state of the cell (119). Relevant to AdV transcriptional regulation and as yet
uninvestigated, SIRT1 has been shown to deacetylate and thereby negatively regulate the HAT
activity of p300 (120), which could in turn negatively regulate expression of AdV genes (111).
Sirtuins have been shown to have broad anti-viral activity, as siRNA knock-down of all
seven sirtuins increases viral titers for both RNA and DNA viruses, including 1.5- to 3-fold
increases in AdV-C5 titers (119). In the same vein, activation of sirtuins through resveratrol
treatment inhibits adenovirus DNA replication of wild-type and vector viruses (118,121,122), but
the mode of action has not been described. This doctoral work shows that sirtuins contribute to
repression of AdV genes in persistently-infected lymphocytes (Chapter 3).
1.4.5

Co-repressive C-terminal Binding Proteins (CtBPs)

The CtBP family of transcriptional corepressors was discovered through their high affinity
binding to AdV E1A proteins (123,124). Mammalian cells express both CtBP1 its homolog CtBP2
(collectively known as CtBP) which can form homo- and hetero- tetrameric complexes, the
assembly and stability of which are dependent on NAD(H) binding (125-128). CtBP complexes
can recruit many different chromatin modulators including Class I HDACs 1 and 2, histone
methyltransferases, E3 ligases and other transcriptional regulators into large transcriptionally
repressive complexes at the promoters of genes ((129), reviewed in (130)). As a result of the
dependence on NAD(H) binding, CtBP has been reported to function as an NAD(H) sensor and
therefore a link between metabolic state and transcriptional regulation (131-133).
The role of CtBP in the AdV lytic life cycle is complex, acting in a repressive or a
potentiating capacity in a situational manner. CtBP has been found to both repress and facilitate
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E1A-289R and -243R-mediated transactivation of viral and cellular genes, respectively (134,135).
CtBP1 and 2 have long been known to suppress the ras-cooperative transformative activity of
E1A, but also appear to enhance E1A transcriptional regulation, possibly through suppression of
the interferon response (123,136-138). Both E1A-289R and -243R interact with high affinity to
both CtBP1 and 2 through a PLDLS-motif located in the shared conserved region 4 (CR4) at the
C-terminal end of the E1A proteins (Figure 1-4). E1A-289R has an additional CtBP-interaction
domain located in the CR3 region unique to this isoform (134), implicating CtBP in regulation of
early genes. Of note, NADH was found to facilitate binding of CtBP to E1A at 1000-fold lower
concentration than NAD+, suggesting that the NAD+/NADH ratio in the cell may affect the
formation of CtBP-E1A protein complexes (131). We show in this doctoral work that CtBP may
have an additional role in repression of E1A expression in a persistent AdV infection in
lymphocytes (Chapter 2).
1.5

Overarching Hypothesis
The overall aim of this work is to identify chromatin modifiers and transcriptional

regulators, known to play a role in repression of AdV gene expression in lytic infection or from
vectors, that may contribute to the transcriptional repression needed to establish a persistent
infection in lymphocytes. Specifically, I hypothesized that Class I, II HDACs, sirtuins, and CtBPs
all play a role in transcriptional repression of persistent infection. I further hypothesized that this
regulation, based on the NAD+ dependence of sirtuins and CtBPs, is inextricably linked to the
dramatic shifts in metabolic state of resting and activated lymphocytes (depicted in Figure 1-7).
Chapter 2 of this work describes experiments done to establish the link between metabolism and
viral gene expression in persistently-infected lymphocytes, and the role of CtBP in repression of
viral genes. Chapter 3 examines the roles that Class I, II HDACs and sirtuins play in repression of
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specific viral genes. Chapter 4 describes additional work to address some technological challenges
to the study of persistent AdV infection. Chapter 5 summarizes major findings and identifies
remaining questions for further study.

Remodeling and
Chromatin Formation

Sirtuins
HDACs
E1A?

(Class I)

Metabolic State
Cofactors: NAD+/NADH

HATs
E1A

CtBPs

Ac
Ac

Ac

ified from Kristie 2015 (HSV):
016/j.virol.2015.01.026

Repressed Viral Chromatin

Active Viral Chromatin

Figure 1-7. Overarching Hypothesis
AdV DNA (shown in purple) enters the nucleus with protein VII (shown in blue). The
viral chromatin is remodeled by cellular histones and subject to transcriptional regulatory
machinery in the cell. Repression of the viral chromatin, through interaction with cellular proteins
dependent on the concentration of metabolic cofactors, is linked to the metabolic state of the
lymphocyte. Modified from (139).
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2

NAD-LINKED MECHANISMS OF GENE DE-REPRESSION AND A NOVEL ROLE
FOR CTBP IN PERSISTENT ADENOVIRUS INFECTION OF LYMPHOCYTES
This article was accepted for publication in Virology Journal on 11/26/2019.

2.1

Abstract
Background: Adenovirus (AdV) infection is ubiquitous in the human population and

causes acute infection in the respiratory and gastrointestinal tract. In addition to lytic infections in
epithelial cells, AdV can persist in a latent form in mucosal lymphocytes, and nearly 80% of
children contain viral DNA in the lymphocytes of their tonsils and adenoids. Reactivation of latent
AdV is thought to be the source of deadly viremia in pediatric transplant patients. Adenovirus
latency and reactivation in lymphocytes is not well studied, though immune cell activation has
been reported to promote productive infection from latency. Lymphocyte activation induces global
changes in cellular gene expression along with robust changes in metabolic state. The ratio of free
cytosolic NAD+/NADH can impact gene expression via modulation of transcriptional repressor
complexes. The NAD-dependent transcriptional co-repressor C-terminal Binding Protein (CtBP)
was discovered 25 years ago due to its high affinity binding to AdV E1A proteins, however, the
role of this interaction in the viral life cycle remains unclear.
Methods: The dynamics of persistently- and lytically-infected cells are evaluated. RTqPCR is used to evaluate AdV gene expression following lymphocyte activation, treatment with
nicotinamide, or disruption of CtBP-E1A binding.
Results: PMA and ionomycin stimulation shifts the NAD+/NADH ratio in lymphocytic
cell lines and upregulates viral gene expression. Direct modulation of NAD+/NADH by
nicotinamide treatment also upregulates early and late viral transcripts in persistently-infected
cells. We found differential expression of the NAD-dependent CtBP protein homologs between
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lymphocytes and epithelial cells, and inhibition of CtBP complexes upregulates AdV E1A
expression in T lymphocyte cell lines but not in lytically-infected epithelial cells.
Conclusions: Our data provide novel insight into factors that can regulate AdV infections
in activated human lymphocytes and reveal that modulation of cellular NAD+/NADH can derepress adenovirus gene expression in persistently-infected lymphocytes. In contrast, disrupting
the NAD-dependent CtBP repressor complex interaction with PxDLS-containing binding partners
paradoxically alters AdV gene expression. Our findings also indicate that CtBP activities on viral
gene expression may be distinct from those occurring upon metabolic alterations in cellular
NAD+/NADH ratios or those occurring after lymphocyte activation.

2.2

Background
Adenovirus infection is ubiquitous in the human population, and the species C subgroup

(AdV-C1, 2, 5, and 6) is the most widespread of these viruses. Species C AdVs cause acute
infection in the respiratory and gastrointestinal tract (1-4). In addition to causing lytic infections
in epithelial cells, adenoviruses have the ability to persist in a non-lytic state in mucosal
lymphocytes (2,5-11).

AdV-C infections occur predominantly in the very young, and

consequently nearly 80% of children contain viral DNA in the lymphocytes of their tonsils and
adenoids (1-4). These infections can be life-threatening for immunocompromised pediatric
transplant patients, and those receiving allogeneic hematopoietic stem cell transplants (allo-HSCT)
are at significant risk for developing disseminated adenovirus disease. Although these infections
and resulting disease can be initiated through de novo exposure to the virus, the predominant cause
in severely immunocompromised patients is endogenous reactivation of AdV-C, types 1, 2, and 5
(3). The AdV-related post-transplantation mortality for these patients is estimated to be between
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3.2 and 6.0%, potentially affecting more than 100 children per year in the U.S. (3,12,13). There is
currently no medical intervention to protect against AdV reactivation, or FDA-approved treatment
for AdV disease, and the mechanisms that allow the virus to persist and induce reactivation are
almost entirely unknown (14,15).
Persistent AdV infections last for long periods of time following resolution of the initial
lytic infection, and the virus can be intermittently detected in fecal samples for months to years
after symptoms have abated (16). Persistent infections in lymphocytes have been reported to
exhibit a range of repressed states, from truly latent (with no production of infectious particles) to
a “smoldering” infection with low viral yield (2,8). Immunoactivation of tonsillar lymphocytes
has been shown to reactivate latent AdV, but the cell-type specific mechanisms behind this derepression have not been studied (2). B and T lymphocytic cell line models of persistent infection
have been established that exhibit long-term persistent AdV infections marked by retention of high
levels of viral genomes and very low viral protein expression (17,18). Interestingly, the persistent
phase in these models has been shown to be regulated, in part, by transcriptional controls not seen
in lytic infections. Several viral genes have been reported to display alternative patterns of
expression when compared to lytic infections, suggesting specific programs of repression are
present in persistent infections of lymphocytes (19-21).
As B and T lymphocytes transition from a resting to an activated state, they undergo
dramatic shifts in gene expression and metabolism to accommodate robust proliferation and
differentiation into effector cells. Programs of gene expression during both resting and activated
states have been shown to be regulated in part by chromatin remodelers and co-repressors,
including DNA methyltransferases (DNMTs), Class I and II histone deacetylases (HDACs), Class
III HDACs (sirtuins), ten-eleven translocation (TET) family proteins, and the C-terminal Binding
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Protein family (22). Because the adenovirus genome is chromatinized through rapid association
with cellular histones upon entry into the host cell nucleus, viral gene expression is likely regulated
by these cellular chromatin-modifying mechanisms and responsive to immunoactivation of the
host lymphocyte (23-25).
The C-terminal Binding Protein (CtBP) family of transcriptional corepressors was
discovered through their high affinity binding to AdV E1A proteins (26,27). Mammalian cells
express both CtBP1 and its homolog CtBP2 (collectively known as CtBP), which both share a 2Dhydroxyacid dehydrogenase domain, RRT-binding domain, and the PxDLS-binding domain
responsible for the interaction with E1A (reviewed in (28)). CtBP homo- and hetero-dimers also
likely form tetramers with the capacity to recruit many different chromatin modulators including
Class I and II HDACs, histone methyltransferases, E3 ligases and other transcriptional regulators
into large transcriptionally repressive complexes at the promoters of genes (28-31). The assembly
and stability of these complexes are dependent on nicotinamide adenine dinucleotide (NAD+ and
its reduced form NADH) binding, and CtBP has been reported to function as an NAD(H) sensor
and therefore a link between metabolic state and transcriptional regulation (30,32-36).
Much has been reported about CtBP and its interaction with the viral E1A proteins.
Initiation of the lytic AdV infection is marked by expression of the immediate early gene E1A,
which has two main protein isoforms - large (13S E1A, 289R) and small (12S E1A, 243R) responsible for transactivating other viral early genes and driving expression of cellular S-phase
genes, respectively (37). Both E1A isoforms interact with high affinity with both CtBP1 and
CtBP2 through a PLDLS-motif located in the shared conserved region 4 (CR4) at the C-terminal
end of the E1A proteins. Large E1A has an additional CtBP interaction domain located in the CR3
region unique to this isoform (38). Of note, NADH was found to facilitate binding of CtBP to E1A
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at 1000-fold lower concentration than NAD+, suggesting that the NAD+/NADH ratio in the cell
may affect the formation of CtBP-E1A protein complexes (32).
The role of the CtBP-E1A interaction in the lytic AdV life cycle is complex and has been
reported to be either repressive or faciliatory, depending on the context. Mutation of the CtBPbinding site in CR4 of E1A drastically reduces virus replication, but stable knock-down of CtBP2
increases viral yield (39,40). CtBP1 and CtBP2 suppress the ras-cooperative transformative
activity of the E1A proteins, but are required for E1B-55K cooperative transformation (26,39,4143). At the level of transcriptional regulation, CtBP has been found to both repress and enhance
E1A transactivation of viral and cellular genes (38,44). In a reciprocal relationship, E1A can exert
influence over CtBP function as well, such as by altering acetylation and repressor-complex
composition (44) and enhancing nuclear localization (45,46). These findings suggest that the high
affinity binding between the E1A proteins and the CtBP proteins could form different contextspecific complexes with finely-tuned functions. Given the complex nature of CtBP function
during lytic infections of epithelial cells, it seems plausible that the CtBP proteins function in yet
a different capacity within the unique cellular backdrop of persistent infection in lymphocytes.
The present study focuses on the mechanisms of viral reactivation in lymphocytes
infected with AdV-C and provides experimental evidence for metabolically-linked mechanisms
that could contribute to viral reactivation following cell activation. We show that viral transcription
in lymphocyte models of AdV persistence is repressed compared to lytically-infected cells, but
that relative amounts across viral transcripts are similar between the two infection types. Our data
reveal that activation of lymphocytes shifts the NAD+/NADH ratio and that viral transcription is
linked to alterations in this ratio. We also report differential expression of the NAD-dependent
CtBP protein homologs between lymphocytes and epithelial cells. Last, our data reveal that

38

inhibition of CtBP interaction with PxDLS-motif binding partners upregulates AdV E1A
expression in T lymphocytes but not epithelial cells. Together, our results provide novel insight
into metabolic factors that can regulate adenoviral reactivation in human lymphocytes.
2.3

Materials and Methods

Cell lines
The human lung carcinoma cell line A549 was purchased from the American Type Culture
Collection (ATCC, Manassas, VA). BJAB (EBV-negative Burkitt’s lymphoma, (47)) and Jurkat
(T cell Acute Lymphoblastic Leukemia [ALL]) were also obtained from the ATCC. KE37
(immature T cell ALL) cells were purchased from the German Collection of Microorganisms and
Cell Cultures (DSMZ, Braunschweig, Germany). Me-180 (HPV-positive cervical carcinoma) and
CaLu1 (lung carcinoma) were obtained from Linda R. Gooding (Emory University, Atlanta, GA).
A549 cells were grown in Dulbecco’s modified Eagle medium (DMEM) with 4.5μg of glucose
per ml, 10% fetal calf serum (FCS), and 10 mM glutamine. BJAB, Jurkat, and KE37 cells were
grown in RPMI medium supplemented with 10% FCS and 10mM glutamine. Me-180 and CaLu1
were grown in McCoy’s medium, 10% FCS, and 10mM glutamine. Cells were routinely evaluated
to ensure the absence of mycoplasma and lymphocyte cell lines were authenticated by Genetica
Cell Line Testing (Burlington, NC).

Adenoviruses
The AdVC-5 mutant virus strain Ad5dl309 is phenotypically wild-type in cell culture and
was obtained from Tom Shenk (Princeton University, Princeton, NJ). Ad5dl309 lacks genes
necessary for evading adaptive immune attack (E3 RIDα and RIDβ proteins as well as the 14,700molecular-weight protein (14.7K protein)) in infected hosts (48).
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Infection of lymphocytes with adenovirus
Infection of lymphocyte cell lines with adenovirus was performed as described previously
(49) with minor modifications. Lymphocytes were collected and washed in serum-free (SF) RPMI
medium, and cell density was adjusted to 107 cells per mL in SF-RPMI medium. Virus was added
to the cell suspension at 50 PFU/cell, spun for 45 minutes at 1000 x g at 25°C, and resuspended
by agitation. Cells were then incubated at 37°C for 1.5 hours with gently flicking every 30 minutes.
The infected cells were washed three times with complete RPMI medium and then resuspended in
complete RPMI medium at 5x105 cells per mL for culture. Cell concentration and viability were
monitored throughout the infection. Replicates for experiments were obtained from independent
infections.

Stimulation of Immune Cell Activation
Lymphocytes were treated for 24 hours with 81nM PMA + 1.35𝜇M Ionomycin (1X
EZCellÔ Cell Stimulation Cocktail, BioVision, Milpitas, CA). Following Fc block treatment (BD
Pharmingen, San Jose, CA), cells were stained with fluorophore-conjugated antibodies against
CD69 (PE, Biolegend, clone FN50) and CD25 (FITC, BioLegend, clone BC96), or stained with
isotype control, and assessed by flow cytometry using LSR Fortessa (Becton Dickinson) and
FlowJo Software (Becton Dickinson).

Drug treatments
Drug treatment concentration and time of exposure were optimized for all cell lines. For
lymphocytic and epithelial cell lines, cells were seeded at a density of 3 x 105 and 1 x 105 cells per
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mL, respectively, in complete medium supplemented with treatment doses of drugs. Treatment
drugs and doses tested include nicotinamide (NAM, Sigma-Aldrich, [2, 5, 10mM]) and NSC95397
(CtBP inhibitor, Tocris, Bristol, UK, [0.5, 1, 5, 10, 20𝜇M]). Cell growth and viability were
assessed by Trypan blue exclusion at 12 (NSC95397 only), 24, and 48 hours (see Appendices).
Experiments utilized the following doses which maintained the viability indicated: NAM-10mM,
>80% for 48 hours; NSC95397-10𝜇M for 24 hours, which maintained >40% viability in
lymphocytes and >70% viability for epithelial cells.

Reverse transcription and quantitative PCR analysis of viral and cellular mRNA levels
RT-qPCR was performed as described previously with minor modifications (50). Briefly,
total RNA was isolated from 1 x 106 cells using the RNeasy Mini Kit (Qiagen Inc., Valencia, CA)
with RNase-free DNase treatment (Qiagen). After spectrophotometric quantification, 200ng of
RNA was reverse transcribed into cDNA in 20𝜇L reactions (Maxima First Strand cDNA Synthesis
Kit, Thermo Fisher Scientific, Waltham, MA). RT-enzyme negative controls were included for
each reaction. Primers and probes were obtained from Integrated DNA Technologies (Coralville,
IA), with sequences specified below. Each cDNA sample was run in duplicate qPCR reactions
using the Maxima Probe/ROX qPCR Master Mix (Thermo Fisher Scientific) with cycling
conditions as described.
For all experiments in which changes to viral gene transcription were assessed and
expression of our housekeeping gene (eukaryotic translation initiation factor 1, [EIF1]) was
unchanged by treatment, we quantified relative amounts of target (fold-change over untreated) as
2$(∆'(,*+,-*,. $∆'(,/0*+,-*,. ) = 2$∆∆'( as described in (51). In experiments using NSC95397, four
different housekeeping genes (GAPDH, HPRT1, ACTB, and EIF1) were all negatively impacted
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by treatment. Because our primer amplification efficiencies are similar, and cDNA was prepared
3

using equal amounts of RNA for all treatments, we used 2$∆'( = 2$('(,*+,-*,. $'(,/0*+,-*,. ) (51) for
each gene separately, and present the down-regulated housekeeping gene for reference. This
formula was also used for comparing relative amounts across different viral transcripts of untreated
samples. We approximate the constant K = 1 (represents the ratio between the target gene and the
housekeeping gene of the number of molecules present at threshold cycle given an initial number
of

molecules,

defined

in

Equation

4

(51)).

For

this,

∗

2$∆'( =

2$('(,*-+5,* 5,0, $'(,78/9,:,,;<05 5,0, ) was used to yield an approximate relative amount of target
compared to the housekeeping gene for each viral gene.

Primers and Probes:
E1A (Sense sequence, 5’- GTTAGATTATGTGGAGCASCCC-3’, anti-sense sequence,
5’-CAGGCTCAGGTTCAGACAC

-3’,

probe

sequence,

5’-6

FAM-

ATGAGGACCTGTGGCATGTTTGTCT-3IABkFQ-3’)

E3GP19K (Sense sequence, 5’-TTTACTCACCCTTGCGTCAG-3’, anti-sense sequence,
5’-GCAGCTTTTCATGTTCTGTGG-3’,

probe

sequence,

5’-6

FAM-

CTGGCTCCTTAAAATCCACCTTTTGGG-3IABkFQ-3’)

TLP HEXON (Sense sequence, 5’-AAAGGCGTCTAACCAGTCAC-3’, anti-sense
sequence,

5’-CCCGAGATGTGCATGTAAGAC-3’,

CGCTTTCCAAGATGGCTACCCCT-3IABkFQ-3’)

probe

sequence,

5’-6

FAM-
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EIF1 (Sense sequence, 5’- GATATAATCCTCAGTGCCAGCA-3’, anti-sense sequence,
5’-GTATCGTATGTCCGCTATCCAG-3’,

probe

sequence,

5’-6

FAM-

CTCCACTCTTTCGACCCCTTTGCT-3IABkFQ-3’)

Quantitative real time PCR analysis of viral DNA levels
Infected or uninfected control cells were washed in phosphate-buffered saline (PBS) and 5
x 105 cells for each sample were lysed in 100μL of NP-40–Tween buffer containing proteinase K,
as described in (5). Samples were tested by real-time PCR for a region of hexon gene that is
conserved among species C adenovirus serotypes. Samples were run in duplicate for each
independent experiment, with cycling conditions as described. Viral genome numbers were
quantified by comparison to an Ad2 DNA standard curve and normalized relative to GAPDH
expression to account for small differences in cell input (5).

Immunoblots for protein detection
Protein

lysates

were

prepared

using

RIPA

buffer

(Sigma-Aldrich)

with

protease/phosphatase inhibitors (Cell Signaling Technologies), and protein concentrations were
quantified using a BCA protein assay (Thermo Scientific). Thirty ug of protein was separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5 to 12%
polyacrylamide gels (Mini-PROTEAN TGX gels, BioRad, Hercules, CA). Proteins were
transferred onto nitrocellulose membranes (Thermo Scientific) overnight at 30mV at 4°C.
Following confirmation of protein transfer with Ponceau S staining (Aqua Solutions, Deer Park,
TX), membranes were blocked at room temperature (RT) with 5% bovine serum albumin (BSA)
for 1 hour, washed three times with Tris-Buffered-Saline with 1% Tween (TBST), and incubated
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with primary antibodies on a rocker overnight at 4°C. Following three washes with TBST,
membranes were incubated with secondary HRP-conjugated antibodies for 1 hour at RT.
Membranes were washed three times with TBST, the HyGLO HRP chemiluminescent reagent
(Denville, Quebec, CA) used as substrate, and signal detected using x-ray film (MTC Bio).
Primary antibodies include CtBP1 (mouse, 612042, BD Transduction Lab, San Jose, CA), CtBP2
(mouse, 612044, BD Transduction Lab), and b-actin (rabbit, D6A8, Cell Signaling, Danvers, MA).
Secondary antibodies used were also from Cell Signaling: HRP-linked anti-rabbit IgG (7074) and
HRP-linked anti-mouse IgG (7076S).

Quantification of total cellular NAD+ and NADH concentrations
NAD+ and NADH concentrations were determined using the bioluminescent NAD/NADHGlo Assay from Promega (Madison, WI). Cells were plated at a density of 1.5-3 x 104 cells per
well in 250μL complete media on 96-well plates. For determining the effects of treatments on
NAD+/NADH ratios, cells were left untreated or drugs added, and all cells were incubated for
times specified in figures. Nanomolar concentrations of NAD+ and NADH were determined
following manufacturer’s instructions by comparison to a standard curve consisting of dilutions of
b-Nicotinamide adenine dinucleotide (N8285, Sigma).

Statistical analysis
Experiments were repeated at least three times unless otherwise indicated. The
experimental data were analyzed using a student’s t-test in GraphPad Prism software. P-values
less than 0.05 were considered statistically significant. Independent infections of lymphocytes
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exhibit a high degree of variability in gene expression preventing the ability to average
observations across infections, thus for some experiments we have shown the results of
independent replicate experiments.

2.4

Results
2.4.1

Viral transcription in persistently-infected lymphocytes is repressed compared to
lytically-infected cells but relative amounts across viral transcripts are similar

Lymphocytic cell line models of infection harbor high levels of viral DNA for long periods
of time, with very low amounts of detectable viral proteins (17,21). As these cell-line infections
progress over time, viral genome levels decline from peak levels during the “acute phase” (1-30
days post infection (dpi)) into the “persistent phase” (> 30 dpi). The viral genome is retained
during persistence for more than 100 dpi at 10-1000 copies per cell (17,18). To further characterize
the persistent phase dynamics, we examined the variability in the viral genome load across several
independent infections. Using qPCR, we quantified viral genome copy number during both the
acute and persistent phases of two persistently-infected lymphocytic cell lines (BJAB and KE37)
and compared those to acutely-infected lymphocytes as well as lytically-infected cells (Jurkat)
(Figure 2-1A). Acutely-infected BJAB and KE37 were found to carry similar viral loads to
lytically-infected Jurkat cells (1 x 108-1 x 1011 copies per 107 cells). These levels are similar to
those previously detected in lytically-infected epithelial cells (1.2 x 1011-1.6 x 1011 copies per 107
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Figure 2-1.Characterization of viral genome quantities and transcriptional repression in
persistently-infected lymphocytes.
A) Viral genome copy numbers determined by qPCR as previously described (5). BJAB,
KE37, and Jurkat were infected with a MOI 50. Error bars show median value with range. Cell
information: BJAB, persistently-infected (n=9) and acutely-infected (n=3); KE37, persistentlyinfected (n=9) and acutely-infected (n=3); lytically-infected Jurkat (n=5). Persistently-infected
lymphocytes were evaluated between 50 to 241 dpi, lytically-infected Jurkat cells were evaluated
at 2 to 4 dpi. B) Viral transcription in persistently-infected lymphocytes was determined by RTqPCR and relative amounts of mRNA calculated as described in Materials and Methods and
normalized to the housekeeping gene EIF1 (which was not affected by infection, and was set to
1). The negative reciprocal was taken for values less than one to show down-regulation on the
same scale. C & D) Relative amounts of viral transcripts E1A-13S, E3gp19K, and hexon in
persistently-infected (C) and lytically-infected cells (D) were determined by RT-qPCR using equal
amounts of RNA. Relative amounts were calculated as described in Material and Methods and
then normalized to E1A (which was set to 1). Experiments repeated at least 3 times with similar
results. BJAB (n=4, 53-60 dpi), KE37 (n=4, 5-82 dpi), Jurkat (n=3, 2-4 dpi), A549 (n=3, 1-2 dpi).
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cells 48 h post-infection with MOI 30) (49). On average, persistently-infected cells harbor fewer
copies of the viral genome than acutely-infected counterparts, though the differences are not
significant (Figure 2-1A). Notably, lymphocyte infections are capable of maintaining 2 to 4-log
differences in quantities of viral DNA infection-to-infection (1 x 105-1 x 109 copies per 107 cells).
This variability in viral genome copy number has also been reported for naturally-infected mucosal
lymphocytes which can range from 1 x 102 to 1 x 107 copies per 107 cells (2,8).
We have previously reported that expression of the adenovirus death protein (ADP) is
repressed in persistently-infected lymphocyte cell lines (21). Krzywkowski et al. (2017) also
showed reduced E1A and MLP mRNA levels in persistently-infected BJAB cells, relative to
lytically-infected HeLa cells even when viral DNA levels were comparably high (19). To extend
these observations to other viral genes we quantified transcription from three genes expressed
during immediate early (E1A), early (E3), and late (hexon) adenovirus infection. Quantities of viral
transcripts from persistently-infected BJAB and KE37 cells were determined relative to a cellular
housekeeping gene EIF1 (which was not altered by infection, data not shown). We compared
persistent quantities to viral transcripts in lytically-infected Jurkat and A549 cells. In lyticallyinfected cells, all viral transcripts were expressed at levels higher than the cellular reference gene
(Figure 2-1B). Interestingly, viral transcription was markedly lower in lytically-infected Jurkat
compared to A549, which may contribute to the delayed lysis reported for this infection (17). As
expected, persistently-infected cells showed severely repressed levels of viral transcripts compared
to lytically-infected cells, suggesting that for a substantial proportion of viral genomes infecting
these cells, transcription is repressed.
While viral gene expression was repressed in persistent infection, we sought to determine
if viral expression of these same three genes (E1A, E3, and hexon) was maintained at expected
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amounts relative to one another. During the course of lytic infections in epithelial cells, the viral
gene expression program follows a well-described progression (52-54). When maximum rates of
transcription are evaluated, E1A mRNA is present in infected cells in lower amounts than that of
E3. Hexon mRNA and other late mRNA quantities are much larger than those of early genes (5456). To directly determine if viral transcript ratios seen in lytic infection were similar in persistent
infection, we quantified relative viral transcription in persistently-infected BJAB and KE37 cells
and compared them to relative transcript amounts in lytically-infected A549 and Jurkat cells. The
fold change of both E3gp19K and hexon mRNA relative to E1A mRNA levels are shown in
Figures 2-1C and 2-1D. On average, E3 was 10-fold greater than E1A while hexon was 30-fold
greater than E1A. Moreover, despite the variability in genome copy number across samples
(Figure 2-1A), relative quantities of E1A, E3gp19K, and hexon mRNA in persistently-infected
cells (Figure 2-1C) are not distinguishably different from ratios in lytically-infected cells (Figure
2-1D), indicating that persistently-infected cells expressing these genes are producing them at
expected ratios.
2.4.2

Cellular activation of infected lymphocyte cell lines upregulates viral gene
expression

Immune cell activation with a cocktail of activating agents (PMA, Ionomycin, IL-2, antiCD3 and anti-CD28) has previously been shown to reactivate viral transcription and induce
production of infectious particles in latently-infected tonsillar lymphocytes (2). To determine if
our infected cell line models would respond similarly, we first confirmed that immune cell
signaling in our lymphocytic cell lines was functional. Cells were activated with PMA/Iono for
24 hours and the surface expression of CD25 and CD69, markers of lymphocyte activation, was
measured by flow cytometry (57). Stimulation induced upregulation of both CD25 and CD69
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compared to basal levels in all three cell lines (Figure 2-2A). We next evaluated viral E1A, E3,
and hexon expression levels after cell activation. Stimulation upregulated viral gene expression in
all three lymphocyte lines compared to untreated cells. Upregulation was most robust in the BJAB
cells (~4-fold, 5-fold, and 3-fold for E1A, E3, and hexon, respectively) and small but detectable in
E1A in the KE37 cells (1.2-fold average increase, Figure 2-2B). Of note, E1A responded in all 3
replicates of infected KE37 while E3 was increased in 2 of 3 experiments. Overall, the viral early
genes were more responsive to stimulation with PMA/Iono than the late gene hexon. In this regard,
a PMA-responsive element has previously been reported in the E1A promoter (58). Further, PMA
has been reported to act synergistically with E1A protein to upregulate E3 expression (59). Thus,
these two actions of PMA at these early genes may contribute to the increases in viral early gene
expression detected here in response to stimulation. Interestingly, PMA/Iono was also able to
upregulate viral early gene expression in lytically-infected Jurkat cells at a level intermediate
between the persistently infected BJAB and KE37 cell lines.
2.4.3

Infection

with

adenovirus

can

reduce

the

NAD+/NADH

ratio

and

PMA/ionomycin stimulation shifts this ratio in lymphocytic cell lines
Lymphocytes remain in a resting state until activated and can undergo dramatic shifts in
transcriptional programs upon activation (60-62), as well as shifts in metabolism resulting in
significant increases in NAD+ and NADH concentrations (63). These changes can impact
transcription via chromatin remodelers dependent upon specific concentrations of metabolites as
co-substrates or co-factors (64). To begin to understand some of the cellular mechanisms behind
the PMA/Iono-induced upregulation of viral gene expression in infected lymphocytes, we first
measured the impact of PMA/Iono stimulation upon cellular NAD+/NADH ratios in our
lymphocytic cell lines. Treatment with PMA/Iono increased the NAD+/NADH ratio in our three
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Figure 2-2.Cell stimulation with PMA and Ionomycin upregulates viral gene expression in
infected lymphocytic cell lines.
A) Infected BJAB, KE37, and Jurkat cells were stimulated with PMA/Iono for 24 hours
and stained with monoclonal antibodies for CD25 (FITC-labeled) and CD69 (PE-labeled) detected
by flow cytometry. Percentages indicate number of cells positive for the indicated marker
following stimulation. Shaded area and open area show untreated and PMA/Iono-treated samples,
respectively. B) PMA/Iono-induced changes to viral gene expression were evaluated in
persistently-infected BJAB or KE37 cells (between 50 to 100 dpi) and lytically-infected Jurkat
cells (2 dpi). Cells were treated for 24 hours with PMA/Iono and changes to viral gene expression
assessed by RT-qPCR. Lytically-infected Jurkat are demarked by the shaded region to differentiate
from persistently-infected cells. Four infected BJAB, three infected KE37, and two infected Jurkat
replicate infections are shown. Fold change is shown over untreated samples (set to 1). Dashed
gray line shows the line of fold change = 1. Error bars show standard deviation in replicate wells.

50

lymphocyte cell lines, with a significant 3.3-fold increase in BJAB (P=0.0006) and a 1.9-fold
increase in Jurkat (P=0.0465) (Figure 2-3A). KE37 had the highest average NAD+/NADH ratio
when untreated. This cell line also had the widest range of NAD+/NADH-ratio values in an
unstimulated state, and though we observed an increase in ratio for KE37 after PMA/Iono
treatment, it was not statistically significant. This cell line also exhibited the smallest increase in
viral gene expression by PMA/Iono (Figure 2-2B).
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Figure 2-3. PMA and ionomycin treatment increases NAD+/NADH ratio in lymphocyte cell
lines.
A) Uninfected cells were treated with PMA/Iono for 4 hours, and total cellular NAD+ and
NADH nM concentrations were determined using a bioluminescent assay with standard curve.
Numbers of replicates: BJAB - untreated, n = 8, treated, n = 3; Jurkat – untreated, n = 8, treated, n
= 3; KE37 – untreated, n = 5, treated, n = 3. Fold-increase in treated over untreated is shown in
bold in the gray bar (mean of the treated/mean of the untreated). Error bars show standard
deviations of the NAD+/NADH ratios. P-values were determined using a student’s t-test. B) Impact
of persistent infection on NAD+/NADH ratios. Total nM NAD+ and NADH were determined in
persistently infected lymphocytes (>50 dpi) as described in Material and Methods. For all samples,
n = 5. Mean and standard deviation of the ratios is shown. P-values were calculated using student’s
t-test.
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In the course of lytic infection of epithelial cells, AdV is known to alter metabolic pathways
of the host cell, such as glycolysis and the tricarboxylic acid (TCA) cycle, to generate the
metabolites and macromolecular precursors demanded by viral replication (reviewed in (65)).
Whether persistent adenovirus infection results in metabolic reprogramming of the host cell is not
known, although persistently-infected cells continue to divide normally as one measure of cellular
activity (17). If viral gene expression is linked to the NAD+/NADH ratio of the cell, and treatments
which increase the NAD+/NADH ratio increase viral gene expression (Figure 2-2B & 2-3A), we
wondered if the NAD+/NADH ratio was reduced in persistently-infected cells where viral gene
expression is repressed. To address this question, we measured the NAD+/NADH ratio in
persistently-infected BJAB and KE37 cells compared with their uninfected counterparts (Figure
2-3B). On average, the NAD+/NADH ratio is reduced in persistently-infected lymphocytes
compared to uninfected controls and approaches significance in KE37 cells (P=0.0817). BJAB
cells, however, have a much lower baseline ratio as compared to KE37 (1.4 vs 6, respectively),
and infection appears to moderately reduce it further, though not to statistically significantly levels.

2.4.4

Direct modulation of the NAD+/NADH ratio can upregulate viral gene
expression in persistently-infected cells

To more directly evaluate the impact that shifts in the NAD+/NADH ratio could have on
viral gene expression, we treated cells with nicotinamide (NAM) which has been reported to
increase the NAD+/NADH ratio (66). As expected, NAM treatment increased the NAD+/NADH
ratio in BJAB (1.3 fold) and more significantly altered KE37 (2.9-fold; P=0.0294). Again, Jurkat
fell in between these 2 cell lines with a 1.9-fold increase (P=0.0706, data not shown). Following
NAM treatment of persistently-infected lymphocytes, we measured the impact of increasing the
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NAD+/NADH on viral gene expression. As shown in Figure 2-4B, treatment with NAM increased
viral gene expression of early and late genes in both persistently-infected cell lines. E1A and E3
expression appeared to be more robustly increased in KE37 as compared to infected BJAB cells.
Moreover, these NAM-induced increases in viral gene transcription could be seen at the protein
level by flow cytometry during the acute phase of infection when viral proteins are expressed at
detectable levels, and both BJAB cells and KE37 cells exhibited increased expression of hexon
protein following treatment with NAM at 20 dpi (data not shown). Interestingly, the increases in
viral gene expression detected, following treatment with either PMA/Iono and NAM, appear to
correspond to the increases detected in NAD+/NADH ratio. In KE37, NAM shifted the
NAD+/NADH ratio 2.9-fold (Figure 2-4A) compared to 1.4-fold with PMA/Iono (Figure 2-3A).
NAM similarly increased viral mRNA more robustly (> 2-fold for all 3 viral genes) (Figure 2-4B)
than did PMA/Iono treatment (< 1.5-fold for E1A only) (Figure 2-2B). In BJAB cells, PMA/Iono
induced a larger shift in the NAD+/NADH ratio than did NAM (3.3-fold compared to 1.3-fold,
respectively). PMA/Iono also induced larger increases in viral gene expression (Figure 2-2B) than
NAM (Figure 2-4B) (> 3-fold compared to < 3-fold). These results suggest that viral gene
expression in lymphocytes could be tied to the NAD+/NADH ratio of the host cell.

2.4.5

Differential expression of CtBP homologs between lymphocytes and epithelial
cells

The AdV genome remains episomal in lymphocytes (17) and associates with cellular
histones in infected cells (24,25,33). CtBP repressor complexes associate with histones to regulate
gene expression and are sensitive to NAD+/NADH levels (35). Moreover, these proteins were
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24 hours. Following RT-qPCR, fold-change in viral is calculated using 2$∆∆'= as described in the
Material and Methods, with untreated sample as reference (set to 1) and cellular gene EIF1 as the
housekeeping gene. Dashed gray line shows fold change = 1. Error bars show standard deviation
in replicate wells. One representative experiment for each cell line is shown. This experiment was
repeated three times with similar results using BJAB cells. This experiment was repeated four
times for hexon in KE37 cells with similar results and twice for E1A and E3 with similar results.
discovred more than two decades ago through their high affinity interactions with AdV E1A
proteins (289R and 243R, large and small E1A respectively) (26,27). E1A large and small proteins
are the first to be expressed upon infection and are critical for auto-activating the E1A gene,
transactivating expression of other early viral genes, and driving the cell into S-phase (67). Thus,
these proteins must be tightly controlled in cells where persistence, and not lysis, is the outcome.
CtBP has paradoxically been reported to both repress and potentiate AdV infections during lytic
infection of epithelial cells (26,38,39,41-44). We thus wanted to investigate if the CtBP proteins
could be involved in the repression of viral transcription during persistent infection in
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lymphocytes. Although CtBP1 and CtBP2 share a high degree of homology, differences in
expression patterns, structure, and localization suggest context-dependent functions of these corepressors. To begin understanding if these proteins could be contributing to AdV gene repression
we first evaluated the CtBP protein levels in our cells and discovered striking differences between
lymphocytic and epithelial cell lines. We found that CtBP2 was undetectable in all lymphocyte
cell lines compared to the lung epithelial cell line A549 (Figure 2-5A). To determine if the high
level of CtBP2 expression was a characteristic of other AdV-permissive epithelial cell lines, we
evaluated two additional epithelial cell lines, Me-180 (cervical) and CaLu-1 (lung) (68,69) (Figure
2-5B). We detected similarly abundant amounts of CtBP2 in these epithelial cells. CtBP1
expression was consistent across the cell lines, with the exception of A549 cells which had the
lowest amount of CtBP1 protein among all the cell lines. Because persistent infection has been
shown to alter expression of some cellular proteins in lymphocytes (17), we confirmed that CtBP1
was expressed at similar levels in both uninfected and persistently-infected lymphocytic cell lines
(Figure 2-5C). Persistent infection also did not alter CtBP2 protein levels in lymphocytes and
remained undetectable (Figure 2-5C). The striking difference in the CtBP expression profiles
between epithelial cells and lymphocytes suggests that CtBP could be impacting adenovirus
infection differently in lymphocytes as compared to what has been previously reported in epithelial
cells (44-46).

2.4.6

Inhibition of CtBP-E1A interaction upregulates E1A 13S expression in T
lymphocyte cell lines

To examine the role CtBP might have on viral transcription in lymphocytes, we utilized
the small molecule inhibitor NSC95397. This compound specifically blocks binding between
CtBP and PxDLS-containing partners and has been shown to disrupt the CtBP1-E1A interaction
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Figure 2-5. Epithelial cells and lymphocytic cells differ in CtBP2 expression.
Western blot analysis of CtBP1 and CtBP2 proteins was performed on epithelial and
lymphocytic cells as described in the Material and Methods. Permissive epithelial cells lines A549
(lung), Me-180 (cervical) and CaLu-1 (lung) are shown. b-actin protein levels were used as a
control for equal protein loading.

(70). First, we confirmed that treatment with NSC95397 did not alter CtBP1 protein levels in
persistently-infected lymphocytes (Figure 2-6A), and CtBP2 likewise remained undetectable (data
not shown). We next examined the effect of NSC95397 treatment on viral gene expression in
persistently-infected lymphocytic cell lines. Treatment of BJAB cells with NSC95397 caused
down-regulation of all viral genes across three independent experiments (Figure 2-6B), however,
E1A expression was the least impacted. E1A mRNA decreased 1.5- to 3-fold compared to the
larger decrease in hexon (4- to 30-fold). Surprisingly, NSC95397 induced a more robust downregulation of the cellular housekeeping gene EIF1 (2-, 4- and 16-fold). We tested 3 additional
housekeeping genes (glyceraldehyde-3-phosphate dehydrogenase [GAPDH], hypoxanthine
phosphoribosyltransferase 1 [HPRT1], and b-actin [ACTB]) across all lymphocyte lines and saw
robust down-regulation of each of them ranging from 2- to 11-fold (data not shown). Interestingly,
the down-regulation of the housekeeping gene in BJAB cells was greater than the down-regulation
observed for E1A. Because of the robust down-regulation of multiple housekeeping genes tested
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Figure 2-6. CtBP-binding inhibitor, NSC95397, differentially impacts AdV gene
expression across lymphocytic and epithelial cell lines.
A) Western blot analysis of CtBP1 protein was performed as described in Materials and Methods
on cell lysates collected with or without 24-hour treatment with NSC95397. Both persistentlyinfected KE37 and BJAB were 66 dpi. B-E) RT-qPCR and analysis to assess viral gene expression
performed as described for NSC95397 treatment in Material and Methods. B) Persistently-infected
BJAB (≥61 dpi, n = 3), C) persistently-infected KE37 (≥80 dpi, n = 3), D) lytically-infected Jurkat
(2 dpi, n = 3). Down-regulated values are shown as the negative reciprocal, which eliminates
values falling between -1 and 1 (indicated by shaded zone). Error bars show standard deviation on
replicate wells. E) Lytically-infected epithelial cells A549 (2 dpi, error bars represent the SD of 3
independent experiments), CaLu1 (2 dpi, n =1, SD of replicate wells), and Me-180 (2 dpi, n = 1,
SD of replicate wells). F) Comparison of average change in E1A expression induced by
NSC95397 treatment in T cell lines (KE37 and Jurkat, data shown in Figures 6C and 6D) and
epithelial cells (data shown in Figure 6E). Shaded zone between -1 and 1 as described above.
Error bars show SD of fold-change values. P-value was determined using student’s t-test.
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in our study, fold-changes in gene expression between treated and untreated cells are shown
without normalization to an endogenous control as described in Material and Methods (51).
Inhibition of CtBP binding with PxDLS-containing partners using NSC95397 also
caused decreases in hexon mRNA in both KE37 cells (2- to 20-fold) and Jurkat cells (5- to 10fold) (Figure 2-6C & 2-6D). CtBP inhibition, however, has a noticeably different effect on E1A
expression in both of these T cell lines where E1A is upregulated by 1.5- to 4-fold. The expression
of E3 was minimally impacted in these cells. These data suggest that CtBP binding with PxDLScontaining partners may be repressing transcription of E1A in T cells and that inhibiting this
binding allows for expression. In contrast, CtBP may paradoxically be necessary for expression of
the viral late gene hexon in lymphocytes, since it was maximally downregulated by NSC95397
treatment in both the B and T cell lines.
All of the lymphocyte cell lines have delayed infection dynamics as compared to
infected epithelial cells (49). In addition, though Jurkat cells undergo a lytic infection with AdVC5, they still exhibit much reduced levels of viral gene expression (Figure 2-1B). To find out if
inhibiting CtBP binding with PxDLS-containing partners would have the same effect on viral
transcription in epithelial cells, we initiated treatment with NSC95397 in lytically-infected
epithelial cells. As shown in Figure 2-6E, NSC95397 treatment had almost no impact on viral gene
expression in A549 cells. Because the lytic life cycle in A549 is rapid and usually complete by 48
hours, we also assessed viral gene expression at 6 hours post-infection (5 hours after the addition
of NSC95397). No effect of NSC95397 treatment could be seen at this earlier time point in
infection (data not shown). Interestingly, when we assessed viral transcription in two other
epithelial cell lines, CaLu1 and Me-180, NSC95397 treatment negatively impacted hexon
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expression, though not nearly to the level observed in lymphocytes, causing 3- to 4-fold downregulation (Figure 2-6E). As with A549 cells, NSC95397 treatment did not induce any
upregulation of E1A in these cells, and there was a negligible impact on the expression of the
housekeeping gene. The significant difference in impact of NSC95397 treatment on E1A
expression between T cell lines and epithelial cell lines (P=0.0012) is shown in Figure 2-6F.
Overall, NSC95397 treatment strongly impacted both cellular and viral gene expression in infected
lymphocytes (both persistently- and lytically-infected) but had much less impact on infected
epithelial cells. Further, the unique gene expression changes do not appear to be wholly related to
the cell sensitivity to NSC95397 toxicity as ME-180 cells displayed sensitivity similar to the
lymphocytic cell lines (data not shown).
2.5

Discussion
Most of what is known about adenovirus is from studies of lytically-infected cells, and

adenovirus latency and reactivation are not well characterized. The virus can be life-threatening
for immunocompromised individuals as well as pediatric transplant patients, however, the
mechanisms that allow the virus to persist, or those that induce reactivation, are almost entirely
unknown. Patient samples have shown that lymphocytes of the tonsils, adenoids (5), and
gastrointestinal tract (8) contain AdV DNA and are presumably the sites of reactivation. The lack
of small-animal models of persistent adenovirus infection has been an obstacle to studying
infection dynamics in vivo, but a study of AdV infection using humanized mice has recently shown
that persistently-infected cells could also be found in the bone marrow (71).
Our previous studies of AdV-infected lymphocytes from tonsils or adenoids suggest
that replicating virus is more common among younger donors, however, high genome copy
number did not appear to correlate with active replication (2). Replicating virus could be detected
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in cells containing a range of genome copy numbers, from as few as 104 to as many as 106 AdV
genomes per 107 cells (2). Our cell line models of persistent lymphocyte infection carry AdV
DNA levels in a range between 1 x 105-1 x 109 copies per 107 cells (Figure 2-1A). Within these
persistently-infected models, many viral transcripts can be detected in low amounts with fewer
than 1% of the cells expressing detectable levels of viral proteins or producing virus (20,21).
The persistent phase of infection has been shown to be regulated, in part, by
transcriptional controls not seen in lytic infections. Murali et al. (2014) determined that the E3Adenovirus Death Protein (ADP) gene is repressed both transcriptionally and posttranscriptionally in cells which harbor persistent AdV infection (21). Krzywkowski et al. (2017)
showed that in persistently-infected BJAB, very few individual cells express E1A mRNA or Major
Late Transcription Unit mRNA at levels comparable to lytically-infected HeLa cells, even when
the cells harbored large amounts of viral DNA (19). In contrast, Furuse et al. (2013) determined
that persistently-infected BJAB expressed amounts of VA RNAI and VA RNAII that were
comparable to those expressed in lytic infections. However, the relative proportion of the two
transcripts differed when compared to lytically infected cells (20). In our current study, we report
low expression of both early (E1A and E3) and late genes (hexon) in infected lymphocytes as
compared to lytically-infected cells (Figure 2-1B). Indeed, the levels of viral transcripts are all
relatively lower than the expression level of the representative housekeeping gene. In contrast,
AdV transcript levels are relatively higher than housekeeping gene expression in both the lyticallyinfected T cells (Jurkat) and lytically-infected epithelial cells (A549). However, we found reduced
levels of viral transcripts in lytically-infected T cells as compared to lytically-infected epithelial
cells revealing that lymphocytes in general have lower levels of AdV gene expression. We
attempted to confirm differences in viral gene expression at the protein level but were unable to
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detect viral proteins which are in low abundance during viral persistence (data not shown). Despite
some degree of transcriptional repression in the lymphocytes, viral mRNA ratios were surprisingly
similar between persistently-infected and lytically-infected cells (Figures 2-1C and 2-1D,
respectively). These findings in lymphocytes are in line with amounts of E1A, E3, and hexon
mRNAs (~4, 35, and 90%, respectively), quantified as a percent of GAPDH, at 36 hours postinfection in normal lung fibroblasts recently reported by Crisostomo et al. (2019) (54).
Immunoactivation of tonsillar lymphocytes has been shown to reactivate latent AdV
causing increases in viral gene expression and productive infection (2). In previous studies, a
cocktail of immune cell stimulators was used including PMA, Ionomycin, IL-2, anti-CD3 and antiCD28, however, no specific mechanisms for viral gene de-repression were determined. In addition,
these prior studies on activation of naturally infected lymphocytes were done using samples that
contained both T cells and B cells together. In the current study, we report that PMA/Iono alone is
sufficient to induce AdV gene expression in B and T cell models of persistent infection, as well as
in lytically-infected Jurkat cells (Figure 2-2B). In addition, we found that the magnitude of change
in viral expression mirrors the change observed in the NAD+/NADH ratio (Figure 2-3A).
PMA/Iono treatment increased total cellular NAD+ and NADH concentrations (data not shown)
and significantly increased the NAD+/NADH ratio in BJAB and Jurkat cells; large increases in
AdV early gene expression were readily observable in these cells by 24 hours. Stimulation,
including PMA/Iono treatment, of resting lymphocytes has been well-documented to shift the
metabolic program from primarily oxidative phosphorylation to glycolysis, which increases lactate
production, increases synthesis of biosynthetic intermediates, and shifts the NAD+/NADH ratio
(63,79,80). Thus, our data support the notion that changes in the metabolic status of lymphocytes
can promote reactivation of AdV gene expression. In the current study, PMA/Iono had the least
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impact on AdV gene expression in KE37 cells which corresponded with the non-significant change
detected in the NAD+/NADH ratio in these cells after treatment. Whether the addition of other T
cell stimulating agents (IL-2, anti-CD3 and anti-CD28) can induce a significant change in this
ratio, as well as more robust changes in AdV gene expression, is still under investigation.
Interestingly, when comparing the basal NAD+/NADH ratios in the two persistentlyinfected cell lines, KE37 and BJAB, a trend toward viral infection reducing the NAD+/NADH ratio
relative to their uninfected counterparts could be seen, though significance was not reached (Figure
2-3B). These samples were evaluated at different times post-infection, and it is intriguing to
speculate that AdV may significantly impact the NAD+/NADH ratio of the cells it persistently
infects at some point during the course of the infection. How the virus would modulate cell
metabolism mechanistically is unclear. Persistent adenovirus infection of B-lymphocytes has been
shown to significantly down-regulate several cellular genes (BBS9, BNIP3, BTG3, CXADR,
SLFN11, and SPARCL (50)), however, none are reported to obviously function in the regulation
of metabolism. Nonetheless, it is possible that some of the other genes identified as altered by AdV
infection could play a role in this effect ((50), and supplemental data therein).
Nicotinamide (NAM), which is recycled by the cellular NAD+-salvage pathway and
converted into NAD+, can be used to manipulate the NAD+/NADH ratio of cells (81). NAM
treatment of persistently-infected cell lines significantly increased the NAD+/NADH ratio in KE37
while a much smaller change was induced in BJAB cells (Figure 2-4A). Nonetheless, increased
viral gene expression could be detected in both cell lines (Figure 2-4B) suggesting that alterations
in this metabolic ratio can induce viral gene expression in lymphocytes. Interestingly, in contrast
to the robust PMA/Iono-induced upregulation of E1A and large increase in NAD+/NADH ratio
seen in BJAB (3.3-fold, Figure 2-2B), there was no apparent change in E1A expression when the
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ratio was only increased 1.3-fold with NAM (Figure 2-4B). A similar relationship is seen between
E1A expression and the shift in the metabolic ratio in KE37, where more E1A expression is seen
following larger increases in the NAD+/NADH ratio (Figures 2-4B, 2-2B). These findings support
a link between metabolic shifts in lymphocytes and the magnitude of AdV de-repression induced.
The link between the metabolic state of cells and gene expression contributes to
lymphocyte functional responses following immune stimulation (64,82,83). This transcriptional
regulation involves chromatin remodelers dependent upon specific concentrations of metabolites
that serve as co-substrates or co-factors (64). CtBP is a well-known repressor of gene expression
that was discovered through its interaction with E1A (26,27,84). CtBP tetramers associate with
epigenetic enzymes forming complexes that modify the chromatin environment through
coordinated histone modifications, allowing for the effective repression of genes targeted by DNA
binding proteins associated with the complex (30-36,85-87). The stability of CtBP tetramers is
dependent upon NAD(H) binding. Because AdV gene expression in lymphocytes is responsive to
shifts in the NAD+/NADH ratio, we investigated whether CtBP, as a reported metabolic sensor,
could be contributing to the transcriptional repression evident in persistent infection. When
comparing CtBP protein levels, we found that our three lymphocyte cell lines only expressed
CtBP1 and that CtBP2 protein could not be detected (Figure 2-5A). CtBP2 expression has
previously been reported to be in low abundance or undetectable in leukocytes, immune tissues,
and lymphocyte cell lines (29). In contrast to the lymphocytes evaluated in our study, A549 cells
expressed high levels of CtBP2 with lower levels of CtBP1 (Figure 2-5B). This finding suggested
that the composition of CtBP complexes in lymphocytes is different than in epithelial cells, and
therefore CtBP may interact differently with viral proteins in lymphocytes than what has been
reported for epithelial cells.
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NSC95397 is a small-molecule inhibitor of CtBP which acts through the disruption of
CtBP binding to PxDLS-containing partners, including E1A (70). Interestingly, treatment with
NSC95397 resulted in mixed changes in expression of AdV genes (Figure 2-6,B-E). E1A
expression was increased in the T cells lines (KE37 and Jurkat) but minimally impacted in the B
cell line (BJAB). In sharp contrast to E1A, hexon expression was consistently downregulated
across all the lymphocyte cell lines. The ability of NSC95397 to impact E1A expression in both a
lytically-infected T cell line as well as a persistently-infected T cell line could indicate a T
lymphocyte specific role for the disrupted interaction. Unlike the impact seen in T lymphocytes,
none of the epithelial cell lines showed an increase in E1A expression with NSC95397 treatment
(Figure 2-6E). Among the epithelial cell lines, A459 showed negligible changes in AdV expression
following treatment with NSC95397 while Me-180 and CaLu exhibited moderate downregulation
of both hexon and E3 (Figure 2-6E). Whether this downregulation is attributable to the higher
amount of CtBP1 present in these two epithelial cell lines as compared to A549 (Figure 2-5B) is
still unclear.
Of note, cell viability, especially that of transformed cell lines, can be negatively
impacted following treatment with NSC95397 (70). In our experiments, we optimized treatment
timing to maintain cell viability at or above roughly 50% (data not shown). NSC95397 also
induced substantial downregulation of multiple housekeeping genes (Figure 2-6,B-D, and
unpublished data), although this effect did not directly relate to the viability of the cells. For
example, among the epithelial cell lines, Me-180 cells exhibited the highest reduction in viability
with treatment (data not shown), however, the housekeeping gene remained unchanged. One
limitation to our study is the inherent variability between individual infections of lymphocytes
which does not allow for averaging of data across independent infections. Nonetheless, our
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primary observations remain consistent between multiple infections, which are shown
individually.
In addition to the use of the small-molecule inhibitor NSC95397, another potential
experimental strategy for understanding the impact of CtBP1 on persistent infection in
lymphocytes is transient knock-down of CtBP1 expression using shRNA or siRNA. Primary
lymphocytes and lymphocytic cell lines are notoriously challenging to transfect using lipid-based
approaches (88), but electroporation has been used successfully to deliver regulatory RNA with
high efficiency (89). In our current study, we attempted to transfect our persistently-infected
lymphocytic cell lines with knock-down siRNA through electroporation and found that
electroporation alone was sufficient to upregulate viral gene expression (data not shown). Future
attempts to use a CtBP1 knock-down approach may include stable transduction with an inducible
shRNA expression vector prior to infection of the lymphocytes, which would allow controlled
expression of the regulatory RNA and resulting CtBP1 knock-down only after the persistent phase
of infection has been established.
CtBP gene regulation is complex with many paradoxical activities reported for its
function. The differences in CtBP expression profile between our cell line models of lytic and
persistent infection suggest that distinctions in known function, structure, and localization of the
two CtBP homologs may be important for infection outcome in these cells. While CtBP1 is
ubiquitously expressed, CtBP2 expression is more tissue and cell-type specific (29). Structurally,
CtBP1 and CtBP2 differ slightly by a nuclear localization signal (NLS) only present in the Nterminal of CtBP2 and a PDZ-binding domain only present in the C-terminal of CtBP1 (90). The
NLS present, and a key p300 acetylation site on lysine 10 within the NLS, are responsible for the
nuclear localization of CtBP2 (45). On the other hand, the localization of CtBP1, which is found
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both in the cytoplasm and the nucleus, is subject to more complex regulation; sumoylation at lysine
K428, in conjunction with the PDZ-binding domain regulate nuclear localization (90). CtBP1 can
also be recruited to the nucleus by a CtBP2-dependent mechanism (91). Additionally, distribution
of CtBP1 between the cytoplasm and the nucleus is also reported to be dependent upon the celltype, further implicating other factors in localization regulation (90-93). How these reported
differences in the complex regulation of CtBP impact the viral life cycle in these cells will require
additional study.
This is the first investigation into a possible role for CtBP in persistent infection of
lymphocytes, and we observed that NSC95397 treatment could release a CtBP-associated
repression of E1A in infected T cell lines. Although the Jurkat infections are lytic and KE37
infections persist for months, both show suppression of viral gene expression relative to epithelial
cells (17). A549 cells produce high levels of viral late proteins within 24 hours of infection, while
Jurkat and KE37 do not achieve peak levels until 1-3 or 3-7 dpi, respectively, despite equivalent
amounts of viral DNA (Figure 2-1A and (17,21)). Transcription is also repressed in both cell lines
relative to A549 (Figure 2-1B). Whether these overall reduced levels of viral transcripts stem from
a repressive mechanism at the E1A promoter remains to be determined, but it seems likely that
repression of the master regulator of AdV infection, E1A, could have a profound influence on the
infection dynamics. We were surprised to find that, under the same treatment conditions, we
observed no de-repression of E1A in BJAB cells. It is possible that the binding partners
incorporated into CtBP complexes between our B and T cell lines may be different, and
additionally, may be influenced by the differences in basal NAD+/NADH ratios detected in our
lymphocyte cell lines (35). These are all areas worthy of further investigation.
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In one of the only other reports of a direct mechanism involved in establishment of
persistent infection, Zheng et al. showed that repression of AdV transcription, resulting from
interferon (IFN) a- and IFNg-induced recruitment of E2F/Rb complexes to the E1A enhancer, was
able to induce persistent infection in primary and normal epithelial cells (72). While IFN-treatment
allowed epithelial cells to survive infection for long periods of time with reduced viral gene
expression in this study, production of infectious virus could be detected at all time points (72).
Notably, upon cessation of IFN-treatment, viral replication rebounded dramatically (72). In
contrast, in both naturally-infected lymphocytes extracted from tonsil and adenoid tissue and in
lymphocyte cell lines, viral transcription is similarly repressed but infectious virus can be detected
only in rare instances (2,17). This suggests that, even without chronic IFN exposure, a more
extensive repression of viral gene expression has occurred in lymphocytes than what was described
for IFN-treated epithelial cells. Whether the IFN-E2F/Rb axis contributes to persistent infection in
lymphocytes has not been determined, but different and/or additional mechanisms of
transcriptional repression likely regulate persistence in lymphocytes.
Other mechanisms of viral transcriptional repression have been reported in AdV infection
of epithelial cells that potentially link the metabolic state of the cell to regulation of persistent
infection through NAD-dependent enzymes. Sirtuins (NAD+-dependent Class III HDACs) have
been implicated in regulation of AdV gene expression. Silencing RNA (siRNA) knockdown of all
seven human sirtuins (SIRT1-7) has been shown to increase AdV-C5 titers by 1.5- to 3-fold (73).
In the same vein, activation of sirtuins through resveratrol treatment inhibits adenovirus DNA
replication(74,75). Another NAD+-dependent enzyme to have been studied in lytic infection is
Poly(ADP-Ribose) Polymerase 1 (PARP1); the AdV E4orf4 protein has been found to increase
production of viral progeny through inhibition of PARP1, which is activated by the infection-
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induced DNA damage response (DDR) (76). PARP-induced synthesis and attachment of long
poly(ADP-ribose) chains to proteins has been shown to regulate cellular transcription through
chromatin remodeling and modification of transcription factors (77,78). Whether sirtuins or
PARP1 contribute to the transcriptional repression of persistent infection needs further
investigation.
2.6

Conclusion
Given the unique interaction of AdV with lymphocytes, and the ubiquitous presence of

AdV in the population, a more thorough understanding of the mechanisms that regulate its
persistence and reactivation are needed. Overall, our data provide novel insight into metabolic
factors that can influence adenoviral infections in activated human lymphocytes and reveal that
modulation of the cellular NAD+/NADH ratio can de-repress adenovirus early and late gene
expression in persistently-infected lymphocytes. Blockade of CtBP binding with its PxDLScontaining partners, including E1A, did not induce the same changes in AdV gene expression
observed by direct manipulation of the NAD+/NADH ratios or lymphocyte activation. Thus, the
increased E1A gene expression observed in T lymphocytes upon disruption of the CtBP interaction
with PxDLS-binding partners likely represents one mechanism of a multi-factorial program of
gene regulation occurring following metabolic shifts and lymphocyte activation.
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3

CONTRIBUTIONS OF CLASS I, II, AND III HDACS TO VIRAL GENE
REPRESSION DURING ADENOVIRUS PERSISTENT INFECTION

3.1

Background
Unlike the lytic adenovirus infection of epithelial cells, persistent infection of lymphocytes

typically progresses to a non-lytic, “smoldering” infection in which replicating virus is rare (1-3).
Lymphocytic cell line models of persistent infection have been established that exhibit long-term
retention of high levels of viral genomes and very low protein expression (2,3). Interestingly, the
persistent phase in these models has been shown to be regulated, in part, by transcriptional controls
not seen in lytic infections. Several viral genes have been reported to display alternative patterns
of expression when compared to lytic infections, suggesting specific programs of repression are
present in persistent infections of lymphocytes (4-6).
Histone deacetylases (HDACs) play an important role in repression of cellular gene
expression through the removal of acetyl groups from lysine residues on histone tails and
condensation the chromatin structure (7). The 18 HDACs expressed in human cells are divided
into four classes based on their homology with yeast orthologs, and can be further categorized
based on ion requirements at the catalytic site: Class I (HDAC 1, 2, 3, 8), Class II (HDAC 4, 5, 7,
and 9), and Class IV (HDAC 11) are zinc (Zn2+)-dependent and Class III (Sirtuins 1-7) are
nicotinamide adenine dinucleotide (NAD+)-dependent (7,8). Class I HDACs are ubiquitously
expressed nuclear proteins and typically have cell type-specific function as part of multi-subunit
repressor complexes, such as Sin3, CoREST, Mi2/NuRD, and SMRT (9,10). Class II HDACs have
cell type-specific expression, shuttle between the nucleus and cytoplasm and have limited catalytic
activity compared to the Class I HDACs (9,11). Class II HDACs are further divided into subclass
IIa and IIb, which contain one or two deacetylase domains, respectively (12). Sirtuins are histone
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deacetylases with a variety of other enzymatic activities in the cell including ADP ribosylation,
desuccinylation, and demalonylation (13,14). The NAD+-dependence of sirtuins also links
function to the metabolic state of the cell (13).
Similar to cellular chromatin, the chromatin structure for several DNA-virus genomes
is also subject to regulation by HDACs, which has been shown to be important for latent or
persistent infection and reactivation (reviewed in (15) and (9)). The CoREST complex containing
HDAC1 has been shown to be important for the establishment of herpes simplex virus 1 (HSV)
latency, and HSV protein ICP50 has been shown to displace HDAC1 from CoREST repressive
complexes during reactivation (16). Human cytomegalovirus (CMV) latency has been shown to
be regulated by hypoacetylation and HDAC3 at the major immediate early gene promoter (MIEP),
and chromatin remodeling of this promoter leads to reactivation (9,17). Epstein Barr Virus (EBV)
latency is strongly regulated by the myocyte enhancer binding factor 2 (MEF2) recruitment of
HDAC4, 5, and 7 to the promoter of immediate early gene BZLF (18). Kaposi’s sarcomaassociated herpesvirus (KSHV) latency is regulated in part by HDAC1, 2, and 7 repression at the
ORF50 promoter, the release of which induces reactivation (15). Although less is known about the
chromatin structure of latent human papilloma virus (HPV), HDAC inhibitor trichostatin A (TSA)
has been shown to upregulate expression from the HPV-16 long-control-region (LCR) (19). The
sirtuins have also been shown to play a role in repression of DNA viruses both through broad antiviral mechanisms (13) and through specific manipulation of key viral genes. Sirtuin-activator
resveratrol (RV) has shown to inhibit early gene expression in HSV (20) and EBV (21), repress
ORF50 in KSHV (22), and block replication of CMV (23). These mechanisms and additional
known mechanisms involving Class I, II, and III HDACs in repression of viral and cellular gene
expression in the life cycle of several DNA viruses are shown in Figure 3-1 (as reviewed in (24)).
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Figure 3-1. Regulation of HDAC function during infection with DNA viruses.
Based on mechanisms reviewed in (24) and (9). Figure modified from (24).

Despite this body of work describing the activity of HDACs in regulating transcription
during the life cycles of multiple viruses, little has been reported on the role of histone deacetylases
in a wild-type AdV lytic infection. This is due, in part, to the rapid progression of the lytic AdV

78

infection where regulation of activation of viral genes is more relevant. For long-term persistent
infections or retention of AdV vectors, HDACs may have a larger impact on gene expression.
Most of what is known about Class I and II HDACs and their activity in regulation of
AdV gene expression has been found through the use of HDAC inhibitors (HDACi). Studies by
other students in the Benson lab have revealed that Class I and II HDACs play a role in repression
of AdV gene expression in persistently-infected cells; TSA upregulates transcription of several
viral genes (Wilms et al., submitted). Published studies from other labs have evaluated the effects
of Class I and II HDAC inhibitors (HDACi) on expression from AdV vector-delivered transgenes.
While HDACi have been reported to increase the efficiency of adenovirus-based oncolytic viral
therapy through the increased expression of viral receptors on the cell surface (25), HDACi also
have been reported to increase expression of genes delivered in the AdV vector (26,27). Various
Class I and II HDACi have been used successfully to upregulate transgene expression in numerous
cell types and lines from a range of host species, including primary bovine or rat muscle cells (28),
human thyroid carcinoma cell lines (27), mouse neuroblastoma cells, HeLa cells, human
neuroblastoma cells, primary human dendritic cells, keratinocytes, and primary rat astrocytes (29),
and rat neurons (30). The broad diversity of vector constructs, and wide array of cellular
backgrounds, in which Class I and II HDACi increase gene expression suggest Class I and II
HDACs act in a non-specific manner to silence foreign DNA.
Sirtuins have also been implicated in regulation of AdV gene expression. Silencing
RNA (siRNA) knockdown of all seven sirtuins has been shown to increase AdV-C5 titers by 1.5to 3-fold (13). In the same vein, activation of sirtuins through RV treatment inhibits adenovirus
DNA replication of wild-type and vector viruses (30-32). How the sirtuins function to repress AdV
replication has not been studied.
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Based on these previous reports, we hypothesized that HDACs would be involved in
repression of AdV gene expression in persistently-infected lymphocyte cell lines. In this chapter,
we first show the differences in expression of Class I and II HDACs between epithelial and
lymphocytic cell lines. We additionally show that Class I HDACs are involved in repression of
late AdV genes but have found no evidence of Class II HDAC enzymatic activity involvement in
AdV repression. Surprisingly, sirtuins seem to positively regulate E1A, but are conversely involved
in repression of late genes. This is the first study to report the contributions of these enzymes
towards maintenance of the persistent AdV-infection of lymphocytes.

3.2

Materials and Methods

Cell Lines and Culture
The human lung carcinoma cell line A549 was purchased from the American Type Culture
Collection (ATCC, Manassas, VA). BJAB (EBV-negative Burkitt’s lymphoma, (33)) and Jurkat
(T cell Acute Lymphoblastic Leukemia [ALL]) were also obtained from the ATCC. KE37
(immature T cell ALL) cells were purchased from the German Collection of Microorganisms and
Cell Cultures (DSMZ, Braunschweig, Germany). A549 cells were grown in Dulbecco’s modified
Eagle medium (DMEM) with 4.5μg of glucose per ml, 10% fetal calf serum (FCS), and 10 mM
glutamine under 8% CO2. BJAB, Jurkat, and KE37 cells were grown in RPMI medium
supplemented with 10% FCS and 10 mM glutamine under 5% CO2. Cells were routinely evaluated
to ensure the absence of mycoplasma and lymphocyte cell lines were authenticated by Genetica
Cell Line Testing (Burlington, NC).
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Adenoviruses
The AdV-C5 mutant virus strain AdV-C5-dl309 is phenotypically wild-type in cell culture
and was obtained from Tom Shenk (Princeton University, Princeton, NJ. AdV-C5-dl309). AdVC5-dl309 lacks genes necessary for evading adaptive immune attack (E3 RIDα and RIDβ proteins
as well as the 14,700-molecular-weight protein [14.7K protein]) in infected hosts (34).

Infection of lymphocytes with adenovirus
Infection of lymphocyte cell lines with adenovirus was performed as described previously
(35) with minor modifications. Lymphocytes were collected and washed in serum-free (SF) RPMI
medium, and cell density was adjusted to 107 cells per mL in SF-RPMI medium. Virus was added
to the cell suspension at 50 PFU/cell, spun for 45 minutes at 1000 x g at 25°C, and resuspended
by agitation. Cells were then incubated at 37°C for 1.5 hours with gently flicking every 30 minutes.
The infected cells were washed three times with complete RPMI medium and then resuspended in
complete RPMI medium at 5x105 cells per mL for culture. Cell concentration and viability were
monitored throughout the infection. Replicates for experiments were obtained from independent
infections.

Optimizing treatment doses (See Appendices)
Drug treatment concentration and time of exposure were optimized for all cell lines. For
lymphocytic cell lines, cells were seeded at a density of 3 x 105 and 1 x 105 cells per mL,
respectively, in complete medium supplemented with treatment doses of drugs. Treatment drugs
and doses tested include Trichostatin A (TSA, Pan HDAC inhibitor, Sigma-Aldrich, [50, 175,
300nM]), Tacedinaline (Class Ia inhibitor, Selleck Chemicals, [2.5, 5, 7, 10𝜇M]), TMP195 (Class

81

IIa inhibitor, Cellagen Technologies, [300, 500, 1000, 1500nM]), Tubacin (Class IIb HDAC6
inhibitor, Santa Cruz Biotechnology, [1, 2, 4𝜇M]), Resveratrol (Sirtuin activator, Calbiochem, [5,
10, 20, 40uM]), and Sirtinol (SIRT1 and SIRT2 inhibitor, Selleck Chemicals, [25, 50, 75𝜇M]).
Cell growth and viability were assessed by Trypan blue exclusion at 24 and 48 hours (see
Appendices). Experiments utilized the following doses which maintained the viability indicated at
48 hours: TSA-175nM, >50%; Tacedinaline-5uM, >70%; TMP195-1000nM, >90%; Tubacin2uM, >60%, Resveratrol-20uM, >40%. Sirtinol was particularly toxic to T cell lines and a
minimum dose of 25uM was used to keep >15% viability and to see transcriptional effects.

RT-qPCR
RT-qPCR was performed as described previously with minor modifications (36). Briefly,
total RNA was isolated from 1 x 106 cells using the RNeasy Mini Kit (Qiagen Inc., Valencia, CA)
with RNase-free DNase treatment (Qiagen). After spectrophotometric quantification, 200ng of
RNA was reverse transcribed into cDNA in 20𝜇L reactions (Maxima First Strand cDNA Synthesis
Kit, Thermo Fisher Scientific, Waltham, MA). RT-enzyme negative controls were included for
each reaction. Primers and probes were obtained from Integrated DNA Technologies (Coralville,
IA), with sequences specified below. Each cDNA sample was run in duplicate qPCR reactions
using the Maxima Probe/ROX qPCR Master Mix (Thermo Fisher Scientific) with cycling
conditions as described. For all experiments expression of our housekeeping gene (eukaryotic
translation initiation factor 1, EIF1) was unchanged by treatment and changes to viral gene
transcription were assessed as relative amounts of target (fold-change over untreated) as
2$(∆'(,*+,-*,. $∆'(,/0*+,-*,. ) = 2$∆∆'( as described in (37).
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Primers and Probes:
E1A (Sense sequence, 5’- GTTAGATTATGTGGAGCASCCC-3’, anti-sense sequence,
5’-CAGGCTCAGGTTCAGACAC

-3’,

probe

sequence,

5’-6

FAM-

ATGAGGACCTGTGGCATGTTTGTCT-3IABkFQ-3’)

E3GP19K (Sense sequence, 5’-TTTACTCACCCTTGCGTCAG-3’, anti-sense sequence,
5’-GCAGCTTTTCATGTTCTGTGG-3’,

probe

sequence,

5’-6

FAM-

CTGGCTCCTTAAAATCCACCTTTTGGG-3IABkFQ-3’)

TLP HEXON (Sense sequence, 5’-AAAGGCGTCTAACCAGTCAC-3’, anti-sense
sequence,

5’-CCCGAGATGTGCATGTAAGAC-3’,

probe

sequence,

5’-6

FAM-

CGCTTTCCAAGATGGCTACCCCT-3IABkFQ-3’)

EIF1 (Sense sequence, 5’- GATATAATCCTCAGTGCCAGCA-3’, anti-sense sequence,
5’-GTATCGTATGTCCGCTATCCAG-3’,

probe

sequence,

5’-6

FAM-

CTCCACTCTTTCGACCCCTTTGCT-3IABkFQ-3’)

Quantitative real time PCR analysis of viral DNA levels
Infected or uninfected control cells were washed in phosphate-buffered saline (PBS)
and 5 x 105 cells for each sample were lysed in 100μL of NP-40–Tween buffer containing
proteinase K, as described in (38). Samples were tested by real-time PCR for a region of hexon
gene that is conserved among species C adenovirus serotypes. Samples were run in duplicate for
each independent experiment, with cycling conditions as described. Viral genome numbers were
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quantified by comparison to an Ad2 DNA standard curve and normalized relative to GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) expression to account for small differences in cell
input (38).

Flow cytometry
Cells were fixed with 1% paraformaldehyde, and membranes permeabilized with 0.2%
Tween in PBS. Intracellular staining for AdV hexon protein was done with primary anti-hexon
antibody (MAB 8051, EMD Millipore Corp, Billerica, MA), and secondary allophycocyanin
(APC)-conjugated anti-mouse IgG antibody (A865, Invitrogen-Life Technologies, Eugene, OR).
A mouse isotype IgG1, 𝜅 antibody (557273, BD Pharmingen) was used to control for non-specific
antibody binding. Detection of antibody-conjugated APC was performed on LSR Fortessa flow
cytometer (Becton Dickinson) and analyzed using FlowJo software (Becton Dickinson).

Immunoblots for protein detection
Protein

lysates

were

prepared

using

RIPA

buffer

(Sigma-Aldrich)

with

protease/phosphatase inhibitors (Cell Signaling Technologies), and protein concentrations were
quantified using a BCA protein assay (Thermo Scientific). Thirty ug of protein was separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5 to 12%
polyacrylamide gels (Mini-PROTEAN TGX gels, BioRad, Hercules, CA). Proteins were
transferred onto nitrocellulose membranes (Thermo Scientific) overnight at 30mV at 4°C.
Following confirmation of protein transfer with Ponceau S staining (Aqua Solutions, Deer Park,
TX), membranes were blocked at room temperature (RT) with 5% bovine serum albumin (BSA)
for 1 hour, washed three times with Tris-Buffered-Saline with 1% Tween (TBST), and incubated
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with primary antibodies on a rocker overnight on at 4°C. Following three washes with TBST,
membranes were incubated with secondary HRP-conjugated antibodies for 1 hour at RT.
Membranes were washed three times with TBST, the HyGLO HRP chemiluminescent reagent
(Denville, Quebec, CA) used as substrate, and signal detected using x-ray film (MTC Bio).
Primary antibodies (rabbit) were all obtained from Cell Signaling (Danvers, MA):
HDAC1(D5C6U), HDAC2 (D6S5P), HDAC3 (D2O1K), HDAC4 (D8T3Q), HDAC5 (D1J7V),
HDAC6 (D21B10), HDAC7 (D4E1L), and b-actin (D6A8). Secondary antibody used was also
from Cell Signaling: HRP-linked anti-rabbit IgG (7074).

3.3

Results
3.3.1

Class I HDACs are ubiquitously expressed, but Class II HDACs are
differentially expressed across cell-line models of infection

Cell-line models of AdV infection have different infection phenotypes. Infection of A549
epithelial cells progresses rapidly towards lysis. Infection of the Jurkat T cell line also produces a
lytic infection, but much more slowly than with A549 (3). BJAB (B cell) and KE37 (T cell) lines
establish a persistent infection marked by high viral genome copy number and low amounts of
detectable viral protein, and therefore would be considered the most highly repressed (3).
Using western blot, we assessed the amounts of Class I HDACs (1, 2, 3) and Class II
HDACs (4, 5, 6, and 7) present in the different cell lines prior to infection to see if there was any
correlation between HDAC expression levels and infection phenotype across the A549, Jurkat,
KE37, and BJAB cell lines (Figure 3-2). In addition, we tested HDAC protein levels in
persistently-infected KE37 and BJAB to see if infection altered expression.

iBJAB

BJAB

iKE37

KE37

Jurkat

A549
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Figure 3-2. Class I and II HDAC protein levels in cell line models of AdV infection.
Two persistently-infected cell lines (iKE37 and iBJAB, >50 days post-infection (dpi)) are
also shown. 𝛽-actin is shown as a loading control.

Class I HDACs were uniformly expressed across all cell lines tested, with the exception of
an additional HDAC2 isoform present in A549 cells. However, differences in the Class II HDACs
were detected, the most notably for HDAC 4 and 7. BJAB appeared to have reduced levels of
HDAC4 compared to the epithelial and T cell lines. Interestingly, the amount of HDAC7 present
had a strong inverse correlation with the infection outcome; A549 had the lowest expression and
has the quickest progression to lysis, whereas the BJAB cell line had the highest expression of
HDAC7 and typically shows the highest degree of viral repression (see Chapter 2, Figure 2-1B).
Only trace amounts of HDAC5 could be detected in all of these cell lines (Figure 3-2), which
seemingly contradicts what has been reported for these cell types; although HDAC5 is most highly
expressed in heart, skeletal muscle, and brain (12), B and T cells have been shown to express
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detectable levels (39). Importantly, persistent infection did not substantially alter expression of the
HDACs we tested.
3.3.2

Enzymatic activity of Class I HDACs, but not Class II, is involved in repression
of AdV genes in persistently-infected lymphocyte cell lines.

We have previously reported that pan-HDAC inhibitor TSA, which has been reported to
inhibit both Class I and Class II HDACs, upregulates AdV gene expression in persistently-infected
cells (Wilms et al., submitted). Here we tried to identify the specific class of HDACs responsible
for the repression of viral genes. We treated persistently-infected cells, greater than 50 days postinfection, with different HDAC inhibitors (Tacedinaline - Class I HDAC inhibitor, TMP195 Class IIa HDAC inhibitor, or TSA – pan-HDAC inhibitor; specificity shown in Figure 3-3) for 48
hours and assessed changes to viral immediate early gene E1A, early gene E3, or late gene hexon
using RT-qPCR.

HDAC11

HDAC10

HDAC6

Class IIb Class IV

HDAC9

HDAC7

HDAC4

HDAC8

HDAC3

HDAC2

HDAC1

HDAC5

Class IIa

Class I

TSA (Control)
Tacedinaline
TMP195
Tubacin

Figure 3-3. Inhibitors of Class I and II HDACs.
Red square indicates a potency (half-maximum inhibitory concentration, IC50) of < 2uM.
Modified from (Lobrera 2013).
These treatment drugs function by inhibiting the deacetylase activity of the HDACs (40).
The Class I inhibitor induced a robust upregulation of E3 (2- to 4-fold) and hexon (3- to 4-fold),
on the same scale or higher than the TSA treatment in persistently-infected BJAB (Figure 3-4).
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E1A did not respond to the Class I inhibitor in the BJAB cell line, but small increases in E1A
expression could be detected in the persistently-infected KE37 cell line. Treatment with the Class
IIa inhibitor did not appear to alter viral gene expression in either cell line, indicating that
enzymatic activity of the Class IIa HDACs is not contributing to viral gene repression (Figure
3-4).
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Figure 3-4. Treatment with Class I, but not Class IIa, HDAC inhibitors increases viral
gene expression in persistently-infected cell lines.
Infected BJAB (55dpi) and KE37 (81dpi) were treated with 5𝜇M tacedinaline (Class I),
1𝜇M TMP195 (Class IIa), or 175nM TSA (pan) for 48 hours. Expression of viral genes E1A, E3,
and hexon were compared to housekeeping gene EIF1 and assessed by RT-qPCR as described in
Materials and Methods. Untreated values for each gene were set to 1. Dotted line demarks a value
of 1 signifying no relative change in expression level. One representative experiment of 2
biological repeats is shown for each cell line. Error bars denote standard deviation on duplicate
wells.

Because the increases in viral gene expression with TSA treatment could be the result of
inhibition of Class IIb HDACs as well (40), we next investigated whether inhibition of Class IIb
HDACs alone would induce changes to viral gene expression. There currently is no HDAC10
inhibitor available, but there are several highly selective inhibitors of HDAC6, including tubacin
and tubastatin A (41). We treated persistently-infected cells with tubacin or TSA for 48 hours and
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assessed viral gene expression using RT-qPCR. Like Class IIa HDACs, the Class IIb inhibitor
again had very little effect on expression of viral genes in either cell line (Figure 3-5). Therefore,
although we did not investigate the contribution of Class IIb HDAC10 or Class IV HDAC11
towards viral gene repression, we concluded that deacetylase activity of Class I HDACs, and not
Class II, is largely responsible for the viral gene repression that is alleviated with TSA treatment.
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Figure 3-5. Treatment with HDAC6 inhibitor (Class IIb) does not alter viral gene
expression.
Infected BJAB (64dpi) and KE37 (78dpi) were treated with 2𝜇M tubacin (Class IIb,
HDAC6), or 175nM TSA (pan) for 48 hours. Expression of viral genes E1A, E3, and hexon were
compared to housekeeping gene EIF1 and assessed by RT-qPCR as described in Materials and
Methods. Untreated values for each gene were set to 1. Dotted line demarks a value of 1 signifying
no relative change in expression level. One representative experiment of 2 biological repeats
shown for each cell line. Error bars denote standard deviation on replicate wells.

3.3.3

Activating Class III HDACs (sirtuins) with resveratrol upregulates E1A
expression.

We described in Chapter 2 (Figure 2-4) that treatment with nicotinamide (NAM) shifts the
NAD+/NADH ratio in persistently-infected cells, and that nicotinamide induces upregulation of
viral genes E3 and hexon in persistently-infected BJAB cells, and of E1A, E3, and hexon in
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persistently-infected KE37 cells. Nicotinamide treatment also acts as an inhibitor of the sirtuin
family of HDACs, which could contribute to the release of repression of AdV gene expression
(42). As sirtuins have been reported to have broad-antiviral activity including the repression of
adenovirus (13), we further investigated the role sirtuins play in persistent infection. Persistentlyinfected cells were treated with sirtuin-activator resveratrol (RV) and changes in viral gene
expression were determined using RT-qPCR (Figure 3-6). Surprisingly, RV-induced sirtuin
activation had opposing effects on E1A and hexon expression.

RV treatment caused an

approximately 2-fold down-regulation of viral late gene hexon in both cell lines, a result that likely
comprises the anti-AdV effect of sirtuins (13,31). Surprisingly, E1A was upregulated by RV
treatment by 1.7-fold in iBJAB and 2.8-fold in iKE37 and to similar levels in replicate experiments
(data not shown). The E3 gene was largely unresponsive to RV treatment indicating that sirtuins
are not involved in regulation of this promoter. Together, these data suggest that the sirtuins play
a role in the repressive transcriptional regulation of AdV gene expression during persistentinfection, but act primarily through repression of late, rather than early genes. Similar to results in
Chapter 2, these data point to differential regulation across early and late viral genes.
3.3.4

Inhibiting SIRT1 and SIRT2 with sirtinol upregulates E3 and hexon in
persistently-infected cell lines.

Sirtuins (SIRT1-7) localize to different subcompartments within the cell.

SIRT1 is

primarily nuclear, but shuttles between the nucleus and the cytoplasm (43). SIRT2 is primarily
cytoplasmic, but moves to the nucleus during certain phases of the cell cycle (44). SIRT3, SIRT4,
and SIRT5 are located in the mitochondria, although a small fraction of SIRT3 resides in the
nucleus (44). SIRT6 localizes to the nucleus, and SIRT7 to the nucleolus (43). SIRT1, SIRT2,
SIRT6 have the most well-studied roles in chromatin remodeling (44,45). In order to further
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identify which sirtuins were involved in repression of the AdV gene expression, we treated
persistently-infected cells with sirtinol, which inhibits SIRT1 and SIRT2 (42), and assessed viral
gene expression through RT-qPCR (Figure 3-7).
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Figure 3-6. Activating sirtuins with resveratrol upregulates E1A and down-regulates
hexon in persistently-infected lymphocytic cell lines.
Cells were treated with 20𝜇M RV for 48 hours (iBJAB) or 24 hours (iKE37), and changes
in viral gene expression evaluated using RT-qPCR as described in Materials and Methods. One
of 4 replicates is shown for iBJAB (> 99 dpi), and one of two replicates is shown for iKE37 (> 80
dpi). All gene expression shown relative to the untreated sample, which was set to one. Dotted line
demarks a value of 1 signifying no relative change in expression level. Error bars show standard
deviation on replicate wells.
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Figure 3-7. Inhibition of SIRT1 and SIRT2 with sirtinol upregulates viral gene
expression.
Cells were treated with 25𝜇M sirtinol for 48 hours, and changes in viral gene expression
evaluated using RT-qPCR as described in Materials and Methods. Persistently-infected BJAB
were at 60dpi, and KE37 were at 77dpi. One experiment for each cell line was performed. All
gene expression shown relative to the untreated sample, which was set to one. Dotted line demarks
a value of 1 signifying no relative change in expression level.
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Inhibiting SIRT1 and SIRT2 with sirtinol upregulated E3 and hexon approximately 1.5fold in iBJAB cells, but E1A was not altered by treatment (Figure 3-7). Sirtinol also upregulated
E3 and hexon in iKE37 cells, but to a higher degree (2.5-fold). Interestingly, E1A was also
upregulated approximately 2.5-fold by sirtinol treatment in iKE37 cells (Figure 3-7). Although
requiring confirmation with replicate experiments, these results show SIRT1 and SIRT2 contribute
to repression of E3 and hexon in persistenty-infected cells. SIRT1 and SIRT2 also contribute to
repression of E1A in KE37 cells.
Interestingly, E3 was upregulated in both cell lines when SIRT1 and SIRT2 were
inhibited with sirtinol (Figure 3-7), but E3 was unaffected with RV-induced sirtuin activation
(Figure 3-6). This difference in effect may have to do with different modes of action and
specificity of the two compounds. Sirtinol is highly specific for SIRT1 and SIRT2, and works by
blocking catalytic activity (46). Resveratrol, on the other hand, activates predominantly SIRT1 and
functions allosterically by inducing a conformational change in the sirtuin and favoring cleavage
of the substrate (47). Because SIRT1 activity is involved in a number of signaling pathways
including NF-𝜅B and forkhead O family (FOXO) (48), direct inhibition of SIRT1 by sirtinol likely
has off-target effects that induce an additive upregulation of viral gene expression. Further
investigation of direct SIRT1 effects through histone modifications or ChIP detection of SIRT1 at
the E3 promoter will be important to confirm SIRT1 involvement in the regulation of this viral
gene.
3.3.5

Long-term sirtuin inhibition with nicotinamide does not prevent establishment of
persistent infection.

AdV infection of lymphocytic cell lines begins with an acute infection in which high levels
of viral proteins are expressed, followed by silencing of viral gene expression as the cells enter the
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persistent phase of infection (3). Because sirtuins were found to be involved in repression of AdV
genes (Figure 3-7), we next investigated whether continued inhibition of sirtuin activity with longterm NAM treatment would prevent the silencing of viral gene expression and block transition to
persistent infection. First, we determined that our lymphocytic cell lines could be treated with
NAM for up to 40 days with no impact on viability (data not shown). To determine the effects of
sirtuin inhibition of viral gene expression, NAM was added to cell culture medium 24 hours prior
to infection, and treated cells were kept in the NAM-supplemented medium for the full 37 days of
the experiment. As Figure 3-8A shows, NAM treatment had little effect on hexon expression
during the acute phase (Days 1-10) of infection when compared to untreated infected cells. By Day
20 in the untreated samples, the number of cells expressing hexon was reduced to less than onethird the peak frequency, from 90% to 25% in the KE37 cells and from 50% to 10% in the BJAB
cells (Figure 3-8A), showing the infections were entering persistent phase as previously reported
(3). Interestingly, NAM treatment dramatically increased the number of KE37 cells expressing
hexon at Day 20, approximately 60% compared to 25% in untreated cells. A small increase in
number of BJAB cells expressing hexon was also seen with NAM treatment at Day 20 postinfection, 17% of NAM treated compared to 11% of untreated cells. This small increase in
frequency of hexon-expressing BJAB cells at Day 20 was seen in an independent biological
replicate (data not shown) and is therefore not likely to be an artifact of the experimental set up.
To confirm that long-term NAM treatment did not alter viral DNA levels, relative quantities of
viral genomes in each sample were assessed by qPCR and found to be unchanged by treatment
(Figure 3-8B). These data show that sirtuins play a role but are not the dominant transcriptionally
repressive force in the silencing of viral gene expression and establishment of persistent infection.
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Figure 3-8. Long-term sirtuin inhibition with NAM does not prevent establishment of
persistent infection.
A) Percent of cells expressing hexon. Cells were untreated or switched to growth medium
supplemented with 3mM NAM 24 hours prior to infection. Cells were infected with AdV-C5dl309 at MOI 50 by standard spin infection as described in Materials and Methods. Percent of
hexon-positive cells was determined using flow cytometry. B) Relative quantities of viral genomes
at Day 37. Viral DNA was assessed by qPCR as described in Materials and Methods, and
normalized to cellular housekeeping gene GAPDH. Error bars show standard deviation on
replicate wells. One representative experiment of two biological repeats with similar results
shown.
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3.4

Discussion
We have shown in this chapter that Class I HDACs (Figure 3-4) and sirtuins (Figures 3-6

to 3-8) contribute to the transcriptional repression of AdV gene expression during persistent
infection of lymphocytic cell lines. These findings join the body of work showing that Class I
HDACs and sirtuins regulate transcription during viral latency or persistent infection by a number
of other DNA viruses, including EBV, CMV, KSHV, and HPV (reviewed in (15) and (9)). Our
experimental approach made use of an array of commercially available HDAC inhibitors and
activators to provide the first evidence of the contribution of these repressive enzymes to the
regulation of AdV persistent infection. We have additionally shown that HDAC activity is more
prevalent in repressing the major late promoter than the early genes, and that the degree of HDAC
involvement may be cell-type specific (Figure 3-7).
The current understanding of the functions of Class II HDACs, especially Class IIa, is
that the predominant role these proteins play in regulation of cellular gene expression is
noncatalytic, but that they promote histone deacetylation through interaction with Class I HDAC3
and the SMRT/NCoR repressive complexes (11,40). However, the Class II HDACs do retain a
functional catalytic site, but the biological function of this activity has not been conclusively
determined. Interestingly, the catalytic activity of Class IIa HDAC5 was recently found to be
involved in stress-induced regulation of gene expression in cardiomyocytes, not through histone
deacetylation, but through regulation of ROS signaling (49). Through treatment of persistentlyinfected cells with the Class IIa HDAC inhibitor TMP195 we showed that the catalytic activity of
these enzymes does not influence the expression of AdV genes during a persistent infection (Figure
3-4).
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While the Class I HDACs were uniformly expressed across the cell line models of
infection, there were differences in expression of the Class II HDACs (Figure 3-2). Notably, the
protein levels of HDAC7 appear to correlate with the degree of viral gene repression, with the
BJAB cell line having the highest level of HDAC7 expression (Figure 3-2) and the highest degree
of repression (Chapter 2, Figure 2-1B). HDAC7 is most highly expressed in lymphocytes and is
important for regulation of B and T cell development (50,51) and for cytokine expression in T
cells (52). In addition, immune cell activation with PMA/iono treatment, which we have shown
upregulates viral gene expression (Chapter 2, Figure 2-2B), causes a rapid relocalization of
HDAC7 from the nucleus to the cytoplasm (39), potentially releasing repressive complexes from
the AdV genome. We have not determined whether the Class II HDACs affect AdV gene
expression through the formation and recruitment of repressive complexes, but this question and
the involvement of HDAC7 will be an exciting area of research to pursue.
RV activation of SIRT1 was found to downregulate late gene hexon approximately twofold (Figure 3-6). RV treatment has previously been shown to inhibit production of infectious
particles in HEK293 cells, but the mechanism of action was not investigated (31). Our data suggest
that downregulation of expression from the major late promoter, which drives the expression of
the structural proteins, may account for the RV-induced reduction in viral titer. Investigation of
the effect of RV treatment on the expression of the other late proteins is needed to confirm this
finding.
The fact that RV treatment and the resulting SIRT1 activation in persistently-infected
cells upregulates E1A expression is surprising (Figure 3-6), and suggests that the virus may have
adapted the sirtuin anti-viral activity to its advantage. E1A expression and downstream early gene
activation were recently found to be repressed by lysine acetyltransferase Tip60, through H4
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acetylation and retention of viral protein VII at the E1A promoter (53). SIRT1 has been found to
be a regulator of Tip60; SIRT1-orchestrated deacetylation of Tip60 reduces its HAT activity and
can lead to proteosomal degradation (44,54). In addition, SIRT1 deacetylates H4 at K16 (43,44).
Based on these studies, it is possible that SIRT1 activation could result in reduced activity of Tip60
and deacetylation of H4 at the E1A promoter, increasing expression of E1A. Whether a
Tip60/H4Ac/VII axis contributes to repression of E1A in persistently-infected cells, and whether
the cellular anti-viral activity of SIRT1 may actually facilitate E1A expression are interesting
questions to answer with future work.

3.5

Conclusion
We have shown in this chapter that Class I and III HDACs contribute to the transcriptional

repression of the AdV genome characteristic of persistent infection of lymphocytes. We have
additionally shown that while sirtuins repress late gene expression, sirtuins may have a paradoxical
activity at the E1A promoter, leading to enhanced expression of the critical E1A proteins. Longterm inhibition of sirtuin function did not prevent the establishment of persistent infection of
lymphocytes, indicating that persistence is likely regulated by complex and multifactorial
mechanisms.
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4

LIMITATIONS

OF

CURRENT

APPROACHES

FOR

THE

STUDY

OF

ADENOVIRUS PERSISTENT INFECTION
4.1

Background
Persistent adenovirus (AdV) infection of mucosal lymphocytes is marked by retention of

viral double-stranded DNA genomes with little to no production of viral proteins or infectious
particles (1,2). While close to 80% of pediatric patients undergoing tonsillectomy test positive for
AdV DNA in extracted lymphocytes, the frequency of infected cells in those samples is quite low,
ranging from 3 to 3,400 cells per 107 lymphocytes (2). Among infected cells from a single patient
sample, large variation in genome copy number per cell has been seen, with an occasional infected
cell containing up to 10-fold more viral DNA than the other infected cells (2). Because a
correlation was found between genome copy number and the presence of replicating virus in these
samples, it is likely that even among these rare infected cells, the viral genome exists in different
active states, making study of the molecular details of the persistent infection in primary
lymphocytes challenging (2).
Lymphocytic cell line models of persistent infection similarly harbor viral genomes
with low or undetectable protein expression for months to years in culture and offer a more readilyaccessible resource to study the mechanics of persistent infection (3,4). Cell-line use allows many
aspects of cell culture and infection to be controlled, and continuous cell division generates ample
material for experimentation purposes with the option for long-term study. Even with the relative
ease-of-use of cell-line models, challenges remain for answering some specific questions that arise
in studying persistent AdV infection of lymphocytes.
First, to reduce variability in any number of outcome measures from experiment-toexperiment, using replicates with similar frequencies of infected cells is desirable. For our
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purposes, we were interested in routinely assessing the frequency of infected cells and correlating
this with the level of viral gene expression to make distinctions between smoldering persistent
infections versus true latently-infected cells. However, determining the number of infected cells
is not trivial; current techniques are labor intensive and expensive, which limits routine
implementation in the lab. This chapter will discuss these current techniques, and our attempts to
use a GFP-expressing virus to determine the frequency of infected cells in culture. Secondly, we
wanted to determine the amount of viral gene expression on viral protein level which was difficult
to ascertain using current antibody-based techniques. Few commercially-produced antibodies
targeting AdV non-structural proteins are available, and this chapter will document challenges
with non-specific binding of currently available antibodies, which impeded our ability to address
this question.

4.2

Materials and Methods

Cell Lines and Culture
The human lung carcinoma cell line A549 was purchased from the American Type Culture
Collection (ATCC, Manassas, VA). BJAB (EBV-negative Burkitt’s lymphoma, (5)) and Jurkat (T
cell Acute Lymphoblastic Leukemia [ALL]) were also obtained from the ATCC. KE37 (immature
T cell ALL) cells were purchased from the German Collection of Microorganisms and Cell
Cultures (DSMZ, Braunschweig, Germany). A549 cells were grown in Dulbecco’s modified Eagle
medium (DMEM) with 4.5μg of glucose per ml, 10% fetal calf serum (FCS), and 10 mM
glutamine. BJAB, Jurkat, and KE37 cells were grown in RPMI medium supplemented with 10%
FCS and 10 mM glutamine. Cells were routinely evaluated to ensure the absence of mycoplasma
and lymphocyte cell lines were authenticated by Genetica Cell Line Testing (Burlington, NC).
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Adenoviruses
The AdV-C5 mutant virus strain AdV-C5-dl309 is phenotypically wild-type in cell culture
and was obtained from Tom Shenk (Princeton University, Princeton, NJ. AdV-C5-dl309). AdVC5-dl309 lacks genes necessary for evading adaptive immune attack (E3 RIDα and RIDβ proteins
as well as the 14,700-molecular-weight protein (14.7K protein)) in infected hosts (6). Ad5GFP,
kindly donated by André Lieber (University of Washington), is a mutant virus containing a
cytomegalovirus promoter-driven enhanced green fluorescent protein (GFP) gene inserted into the
E3 region (7). This virus was constructed in the pJM17 background (personal communication
from Dr. Lieber, August 13, 2019), and the E3 genes of pJM17 are largely intact, but nonfunctional
(8).

Infection of Lymphocytes with Adenovirus
Infection of lymphocyte cell lines with adenovirus was performed as described previously
(9) with minor modifications. Lymphocytes were collected and washed in serum-free (SF) RPMI
medium, and cell density was adjusted to 107 cells per mL in SF-RPMI medium. Virus was added
to the cell suspension at 50 PFU/cell, spun for 45 minutes at 1000 x g at 25°C, and resuspended
by agitation. Cells were then incubated at 37°C for 1.5 hours with gently flicking every 30 minutes.
The infected cells were washed three times with complete RPMI medium and then resuspended in
complete RPMI medium at 5x105 cells per mL for culture. Cell concentration and viability were
monitored throughout the infection. Replicates for experiments were obtained from independent
infections.
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Flow Cytometry
Cells were fixed with 1% paraformaldehyde, and membranes permeabilized with 0.2%
Tween in PBS. Intracellular staining for AdV hexon protein was done with primary anti-hexon
antibody (MAB 8051, EMD Millipore Corp, Billerica, MA), and secondary allophycocyanin
(APC)-conjugated anti-mouse IgG antibody (A865, Invitrogen-Life Technologies, Eugene, OR).
A mouse isotype IgG1, 𝜅 antibody (557273, BD Pharmingen) was used to control for non-specific
antibody binding. Detection of antibody-conjugated APC and expressed GFP was performed on
a LSR Fortessa flow cytometer (Becton Dickinson) and analyzed using FlowJo software (Becton
Dickinson).

Fluorescent Imaging Technology
In fresh cell samples, GFP expression and frequency of GFP-positive cells were assessed
using the Cellometer Auto2000 (Nexcelom Bioscience). Uninfected cells were used as a negative
control.

Immunoblots for protein detection
Protein

lysates

were

prepared

using

RIPA

buffer

(Sigma-Aldrich)

with

protease/phosphatase inhibitors (Cell Signaling Technologies), and protein concentrations were
quantified using a BCA protein assay (Thermo Scientific). Thirty ug of protein was separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5 to 12%
polyacrylamide gels (Mini-PROTEAN TGX gels, BioRad, Hercules, CA). Proteins were
transferred onto nitrocellulose membranes (Thermo Scientific) overnight at 30mV at 4°C.
Following confirmation of protein transfer with Ponceau S staining (Aqua Solutions, Deer Park,
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TX), membranes were blocked at room temperature (RT) with 5% bovine serum albumin (BSA)
for 1 hour, washed three times with Tris-Buffered-Saline with 1% Tween (TBST), and incubated
with primary antibodies on a rocker overnight at 4°C. Following three washes with TBST,
membranes were incubated with secondary HRP-conjugated antibodies for 1 hour at RT.
Membranes were washed three times with TBST, the HyGLO HRP chemiluminescent reagent
(Denville, Quebec, CA) used as substrate, and signal detected using x-ray film (MTC Bio). AntiE1A antibody (Ad2/Ad5, clone M73) was generously provided by David Ornelles (Wake Forest
University). Anti-E2 DNA-binding protein antibody (clone B6-8) was kindly provided by Arnold
Levine (Princeton University) (10). Anti-b-actin monoclonal antibody (clone D6A8) was from
Cell Signaling (Danvers, MA). Secondary antibodies used were also from Cell Signaling: HRPlinked anti-rabbit IgG (7074) and HRP-linked anti-mouse IgG (7076S).

4.3

Results: Part A - Determining the Frequency of AdV-Infected Cells in a PersistentlyInfected Cell Culture
No AdV gene product, either mRNA, non-coding (nc)RNA, or protein, has been found to

be associated with persistent infection, so current methods to determine the infection status of a
cell require detection of viral DNA. The most sensitive technique is the limiting-dilution assay;
infected cells are “diluted” at different ratios with non-infected cells, lysed, and screened for AdV
DNA using nested PCR (2). The lower threshold of this technique described for the detection of
AdV DNA is 3 viral genomes per 107 cells (2). Determining the precise number of infected cells
requires at least four wells for each dilution, and the sensitivity of the assay increases with an
increased number of dilutions, requiring a minimum of six dilutions (11). As described in Garnett
et al. 2009, to determine the infected-cell frequency, the fraction of positive wells is plotted as a
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function of the dilution (in number of infected cells), and a curve of best-fit generated (2). Based
on the Poisson distribution, the point on the best-fit curve corresponding to 63% positive wells
also corresponds to the dilution at which there is one-infected cell per well, yielding the frequency
of infected cells in that sample. Because the viral load in a persistently-infected cell culture can
fluctuate over time (3), this assay would need to be performed prior to each time point for every
independent infection or biological replicate in an experiment to get an accurate number, quickly
becoming an unwieldy and expensive endeavor with increased number of samples.
Another highly sensitive alternative to the limiting-dilution approach for detection is to
use fluorescence in-situ hybridization (FISH) to detect viral genomes (12-15). This technique is
commonly used for detection, quantification, and spatial resolution of nucleic acid sequences, but
implementation is not trivial. Protocols need to be developed and validated, and procedures, which
are probe- and sample-specific, must be optimized empirically (16). As with the limiting-dilution
assay, the time- and cost-intensive nature of the FISH technique makes it impractical when
multiple time-points and large numbers of samples are needed.
A different option for determining infected-cell frequency for persistently-infected cells
would be incorporation of a transgene reporter into the incoming virus which would signal the
presence of the viral genome for long periods of time. Through a generous gift from Dr. André
Lieber at University of Washington Department of Medicine, we procured a mutant AdV-C5 virus
with the E3 region disrupted by insertion of the GFP gene driven from the cytomegalovirus (CMV)
major immediate early-gene promoter (MIEP), called Ad5GFP (7). Many of the AdV early gene
E3 protein products have been found to be dispensible for a wild-type infection phenotype in
culture (6), and because the reporter was driven from a highly active, non-native promoter, we
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hypothesized that this virus would 1) establish persistent infection, and 2) continuously express
GFP in infected cells, allowing us rapid determination of infected-cell frequency in our cultures.
4.3.1

Ad5GFP establishes persistent infection in BJAB and Jurkat cell lines, but
GFP expression is repressed alongside AdV genes

Two lymphocytic cell lines which support persistent infection (BJAB – B cell line and
KE37 – T cell line) and one lymphocytic cell line, which progresses to lytic infection (Jurkat – T
cell line), were infected with Ad5GFP, and expression of GFP and AdV hexon protein were
measured by flow cytometry during the first 16 days of infection. As seen in Figure 4-1, peak
expression of viral genes occurs relatively quickly (Day 6) for infected Jurkat cells, and several
days later (Day 11) for BJAB cells, as has been previously reported (3). At these time points,
approximately 80% of Jurkat and BJAB cells were expressing both hexon and GFP, an indication
that the vast majority were well-infected. Surprisingly, hexon and GFP expression were never
detected in more than 5% of KE37 cells (Figure 4-1B), an effect seen in multiple attempts to infect
this cell line (data not shown). The cause of these thwarted efforts to infect KE37 has not been
determined with Ad5GFP.
In both of the BJAB and Jurkat cell lines (Figures 4-1A and B), hexon expression was
detected in a higher percentage of cells at the earliest time point than GFP, approximately 10%
higher in BJAB and 20% higher in Jurkat, indicating that these genes may be subject to different
regulation in the infected cells in the early stage of infection. However, by Day 17 post-infection
(dpi) for BJAB, both hexon and GFP were detected in far fewer cells. This decrease appears to
correspond to the repression of viral genes seen as persistently-infected cells transition from the
acute phase of infection to the persistent phase (3), and not through lysis of infected cells as
viability remained above 90% (data not shown). Despite regulation through the CMV promoter,
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the GFP was also down-regulated to approximately the same level as hexon in BJAB cells (fewer
than 20% cells positive) and expression appears to be subject to similar mechanisms of repression.
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Figure 4-1. Percent of cells expressing GFP and hexon during acute infection with
Ad5GFP in lymphocyte cell lines.
A) BJAB, B) KE37, and C) Jurkat cell lines shown. Cells were infected with MOI 50
following standard spin protocol (see Materials and Methods), and GFP and hexon protein
expression detected by flow cytometry at Days 3, 5, 11, and 17 post-infection. One representative
infection of n = 2 for BJAB, n = 3 for KE37, and n = 5 for Jurkat is shown.
The Jurkat cell line typically progresses towards lysis when infected with AdV-C5
(3,17); however, Jurkat infection with the Ad5GFP virus establishes persistence. The Ad5GFP
virus has no functional E3 proteins (8), including the E3-11.6-kDa Adenovirus Death Protein
(ADP), which has been shown to be essential for lytic infection in lymphocytes (17). The lack of
ADP expression is presumably what allows the Jurkat cells to remain infected with the Ad5GFP
virus, but this has not been directly evaluated in this model. Although the infected Jurkat cells
continued to express higher levels of both hexon protein and GFP than the BJAB cells, there was
still a substantial decline in the number of cells expressing either protein by Day 17 p.i. from 80%
at peak infection to roughly 50% (Figure 4-1C). The Ad5GFP virus thus does establish persistent
infection in BJAB and Jurkat cells, but expression of the reporter is repressed similarly to the
adenovirus native genes.
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4.3.2

Repressed GFP and hexon genes respond to histone deacetylase (HDAC)
inhibition and phorbol 12-myristate 13-acetate (PMA) ionomycin (Iono)
treatment in persistently-infected Jurkat cells

Ad5GFP persistent infection in Jurkat cells was sustained for over 50 days in culture with
low viral protein and GFP-reporter expression (data not shown); similar long periods of time for
AdV-C5 persistent infection have been documented for other lymphocytic cell lines (3,4). HDACmediated repression of CMV promoter-driven transgenes delivered by AdV-based vectors has
been documented (18), a mechanism we predicted could contribute to the silencing of the GFP
reporter in our Ad5GFP genome. To determine if the repression of the GFP reporter gene was
HDAC-mediated, we treated Ad5GFP-infected Jurkat cells at Day 33 p.i. with the pan-HDAC
inhibitor trichostatin A (TSA), and determined the percent of cells expressing GFP using
fluorescent imaging cytometry. As shown in Figure 4-2, TSA treatment increased the number of
GFP-positive Jurkat cells from approximately 10% to 30%, indicating that the reporter was being
expressed in only one-third or fewer of the cells actually containing viral DNA, and that the
repression was HDAC-regulated. In contrast, infected BJAB cells at Day 33 p.i. showed no
detectable GFP expression before or after treatment (Figure 4-2), and as no PCR to detect viral
genomes was performed, loss of the viral DNA cannot be ruled out.
PMA/Iono treatment is commonly used to simulate immunoactivation of immune cells
through induction of the T- and B-cell receptor-linked signaling pathways (19,20). Because
PMA/Iono treatment has been shown to upregulate viral gene expression and induce production
of infectious virions in naturally-infected tonsillar lymphocytes (2), we wanted to see if PMA/Iono
treatment would upregulate expression of the repressed GFP-reporter gene. We also wanted to
further assess if GFP expression would mirror hexon gene expression. Persistently-infected Jurkat
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Figure 4-2. Treatment with HDAC inhibitor TSA increases number of cells expressing GFP
reporter gene in persistently-infected Jurkat cells.
Infected BJAB or Jurkat cells, at 33 days p.i., were treated for 24 hours with 150nM TSA.
Percent of cells expressing GFP was determined by fluorescent imaging cytometry. One
experiment for each cell line was performed.
cells, at Day 21 or Day 50 p.i., were treated for 24 hours with PMA/Iono, and the percent of cells
expressing GFP or hexon protein determined by flow cytometry (Figure 4-3).

PMA/Iono on GFP and Hexon
Percent of Positive Cells

100

iJurkat_T21 Untreated
iJurkat_T21 PMA/Iono

80
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iJurkat_T50 PMA/Iono

60
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0
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Hexon

Figure 4-3. Treatment with PMA/Ionomycin increases number of cells expressing GFP and
hexon in persistently-infected Jurkat cells.
Persistently-infected Jurkat cells at Day 21 p.i. (bars with black outlines) or at Day 50 p.i.
(bars with gray outlines) were treated with PMA/Iono and percent of GFP- or hexon-expressing
cells determined by flow cytometry. Solid bars are untreated samples, and patterned bars are
PMA/Iono-treated.
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The cells at Day 50 p.i. had lower percentages of both GFP- and hexon-expressing cells than
the cultures at 21 days p.i., showing a time-dependent downward trend for viral protein expression
similar to what has previously been reported for cell line models of persistent infection (3). In
untreated samples from both cultures, the number of GFP-expressing cells was substantially higher
than the number positive for hexon. While this discrepancy may reflect a true difference in
expression levels, it may also reflect an inferior detection capacity of the hexon antibody compared
to the direct detection of the expressed GFP. Interestingly, the number of GFP- and hexon-positive
cells both approximately doubled in response to the PMA/Iono treatment, showing that both the
reporter and the viral late gene have regulatory elements in common. These data also add additional
support for PMA/iono signals being able to increase viral gene expression at the protein level in
addition to the mRNA level (Chapter 2, Figure 2-2B). In addition, these data again demonstrate
that at least half of the untreated infected cells were not expressing detectable levels of GFP or
hexon.
4.4

Conclusions: Part A - Determining the Frequency of AdV-Infected Cells in a
Persistently-Infected Cell Culture
While we were able to establish persistent infection with the Ad5GFP virus in Jurkat cells,

this virus is a sub-optimal reporter virus for several reasons. First, the GFP expression is repressed
to a similar degree as the late gene hexon (Figure 4-3), so cannot give a direct measure of the
number of infected cells. Second, the failed infection of KE37 cells (Figure 4-1) and the possible
loss of viral DNA by Day 33 in the BJAB cell line (Figure 4-2) suggest that Ad5GFP may be lessfit than wild-type virus for establishing persistent infections. Further characterization and
optimization of Ad5GFP infection in BJAB and KE37 needs to be done to determine if long-term
infection can be established in these lines. Despite these shortcomings, the use of the reporter
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virus to establish persist infections in combination with PMA/Iono treatment could be a potential
means to quickly obtain an estimate of the number of infected cells without having to perform a
time-consuming limiting-dilution assay. Additional studies to establish that persistent infections
of KE37 and BJAB with Ad5GFP are possible, an evaluation of the responsiveness of the GFP
reporter to PMA/Iono in these cell lines, and validation with a limiting-dilution assay need to be
done to determine the usefulness of an Ad5GFP/PMA-Iono approach to determining the number
of infected cells in these cultures. In addition, these data add additional support for PMA/iono
also being able to increase viral gene expression in infected lymphocytes.

4.5

Results: Part B - Detection of Viral Proteins in Low Abundance
In our studies to understand the transcriptional repression of the AdV genome in

lymphocytes, we have used several different agents, such as inhibitors and activators of known
transcriptional repressors, and assessed the impact of those agents on viral gene expression at the
level of transcription. Detection of mRNAs, even in very low abundance, is possible with reverse
transcription – quantitative polymerase chain reaction (RT-qPCR) because this approach involves
amplification of the target. To determine if changes to transcription levels are biologically relevant,
the protein products of those viral genes should also be assessed. Detection of viral proteins in
very low abundance can be challenging and is almost entirely dependent on the quality of available
antibodies to target them.
The most commonly used technique for detection and semi-quantification of specific
proteins in a sample is the western blot, or immunoblot, which when optimized, can detect
picomolar amounts of target protein (21). The main limitation of western blotting is the quality of
the antibody, which must have specificity for the target and recognize the target in partially
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denatured form (21). While additional steps can be taken to increase detection of low-abundance
target protein in the sample, such as enrichment through immunoprecipitation or combinatorial
peptide ligand libraries (CPLL) or depletion of common large proteins like IgG through
immunodepletion, these procedures either still require high-quality antibodies or are very highcost (22). The following sections describe our attempts to determine if low abundance viral
proteins could be detected with available antibodies in order to assess the biological relevance of
experimentally-induced changes to transcriptional levels of the corresponding genes.
4.5.1

E1A proteins are not detectable in persistently infected KE37 and BJAB cell
lines due to non-specific binding of anti-E1A antibody

The AdV immediate early gene E1A protein products (289R and 243R) are the first
expressed in the course of lytic infection, and essential to activating the other early genes and
preparing the cell for viral replication (23). Logically, E1A protein expression must be tightly
controlled during persistent infection, but whether they function in any capacity towards
persistence is not known. To determine if we could detect the E1A proteins in persistently-infected
lymphocytes, we prepared cell lysates and performed western blot using the most commonly-used
antibody against the E1A protein products (M73 clone, (24)) (Figure 4-4). In addition, we tested
lysates from infected lymphocytes treated with the small molecule inhibitor, NSC95397, which
disrupts C-terminal Binding Protein (CtBP) repressor complexes (25). As shown in Chapter 2,
Figure 2-6, NSC95397 treatment induces upregulation of E1A transcription in T-cell lines, and we
hypothesized that NSC95397 treatment would induce increases in E1A proteins as well.
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Figure 4-4. Immunoblot for E1A in persistently-infected lymphocytes.
Panel A: Persistently-infected cell lines, Jurkat 36 days post infection (dpi, Ad5GFP),
KE37 and BJAB 66 dpi (AdV-C5-dl309). Each cell line was untreated or treated with 10 𝜇M
NSC95397 for 24 hours as indicated. Positive control is Jurkat infected with Ad5GFP 36 dpi,
which expresses wild-type E1A proteins, >20% of cells GFP+ (data not shown). Panel B:
Uninfected cell lines, untreated or treated with 10 𝜇M NSC95397 for 24 hours. Positive control
same as Panel A. 𝛽-actin used as loading control.
As shown in Figure 4-4A, E1A protein could be detected in persistently-infected Jurkat
cells (which served as our positive control), and was dramatically down-regulated by NSC95397
treatment. Bands of similar size to the E1A protein products were also detected in the infected
KE37 and BJAB cell lines, but at much lower levels. To determine whether the proteins detected
in the infected KE37 and BJAB cell lysates were E1A or not, a panel of uninfected cell lysates,
with or without NSC95397 treatment were run as shown in Figure 4-4B. Non-specific binding of
the E1A antibody could be detected in the same protein-size range in all lymphocyte cell lysates.
As a result we could not differentiate between low amounts of E1A protein and non-specific
binding of the antibody.
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4.5.2

E2 DNA-binding protein is detectable in persistently-infected T cell lines

To see if detection of other AdV early genes in persistently-infected cells was possible, a
western blot targeting the E2 DNA-binding protein (DBP) was performed on the same persistentlyinfected cell lines untreated or treated with NSC95397 (Figure 4-5). The E1A 289R protein is
essential for the transactivation of the E2 early gene. This gene encodes the viral DNA polymerase,
DBP, and the precursor terminal protein, which are all needed for viral DNA replication (26,27).
Figure 4-5A shows the detectable E2 DBP in persistently-infected lymphocytic cells lines
compared to acutely infected A549 epithelial cells (first column). DBP could be detected with a
strong signal in both persistently-infected T cell lines (Jurkat and KE37), with a substantially
higher amount present in the Jurkat cells. The E2 proteins from infected lymphocytes appear to
have migrated at a slower rate than those in A549 lysates, suggesting the presence of some posttranslational modifications not present in the epithelial cell line (Figure 4-5A). NSC95397
treatment does appear to slightly upregulate DBP in both T cells lines as well, suggesting that
CtBP complexes may play a role in repressing E2 expression at the protein level. The E2
immunoblot of uninfected cell lysates (Figure 4-5B) shows that, like the E1A antibody, the E2
antibody also binds non-specifically to cellular proteins of roughly the same size as the viral target.
Interestingly, DBP could not be detected in infected BJAB cells above the background levels
(uninfected cells shown in Figure 4-5B), despite detectable levels of the E2 transcript (data not
shown).
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Figure 4-5. E2 DNA-binding protein is detectable in persistently-infected T cells.
Panel A: Acutely infected A549 cells at 2 days post-infection (dpi, AdV-C5-dl309),
persistently-infected cell lines, Jurkat 36 dpi (Ad5GFP), KE37 and BJAB 66 dpi (AdV-C5-dl309).
Each cell line (except A549) was untreated or treated with 10 𝜇M NSC95397 for 24 hours as
indicated. Two positive controls are acutely infected A549 and Jurkat infected with Ad5GFP 36
dpi, >20% of cells GFP+ (data not shown). Panel B: Uninfected cell lines, untreated or treated with
10 𝜇M NSC95397 for 24 hours. Positive control is untreated infected KE37 shown in Panel A.

4.6

Conclusions: Part B - Detection of Viral Proteins in Low Abundance
Expression of AdV hexon (3) and E3 (ADP, (17)) have been shown to be repressed in

persistently-infected lymphocytic cell lines at both the transcriptional and post-transcriptional
levels. To fully characterize these mechanisms of repression and those repressive mechanisms
acting at other AdV genes, detection of changes in gene expression at both the transcript and
protein levels is important. Through the use of RT-qPCR, low abundance transcripts can be
detected, but detection of low abundance proteins remains problematic. Our initial attempts have
revealed that the commonly used E1A monoclonal antibody (clone M73), binds to multiple
lymphocyte proteins of the same approximate size as the E1A proteins in uninfected lymphocytic
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cell line extracts (Figure 4-4B), potentially masking any signal from low abundance E1A proteins
and making interpretation difficult.
The E2 DBP protein appears the be more highly expressed and therefore easily
detectable in persistently-infected T cell lines than E1A. Although to a lesser degree than the E1A
M73 antibody, the E2 DBP B6-8 antibody also shows binding to cellular proteins of the same
approximate size as the DBP protein (Figure 4-5B), again making any weak signals difficult to
interpret.
4.7

Future Work
To decrease variability across experiments and to gain a more complete understanding of

the dynamics of persistent adenovirus infection of lymphocytes, the capacity to detect and quantify
viral genomes on a single cell basis will be critical for future work. Development and optimization
of a viral genome-embedded reporter which is not subject to transcriptional repression and which
can be easily detected without amplification would be ideal, but clearly this is no easy feat. To
determine whether viral proteins are being expressed in low abundance, more specific antibodies
are needed. Establishing persistent AdV infections with viruses engineered to express tagged viral
proteins, such as MYC or FLAG, may be a way to determine viral protein expression in low
abundance in future work.
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5
5.1

CONCLUSIONS AND FUTURE STUDIES

Discussion
Pediatric patients receiving hematopoietic stem cell transplants (HSCT) are at significant

risk for developing disseminated adenovirus (AdV) infection, with AdV-related posttransplantation mortality between 3.2 and 6.0% (1,2). For the most severely immunocompromised
patients, reactivation of latent adenovirus from persistently-infected lymphocytes is the
predominant cause of a deadly viremia (2). The mechanisms that allow the virus to persist, or
those that induce reactivation, are almost entirely unknown.
The goal of this doctoral work was to elucidate the cellular mechanisms contributing to the
maintenance of the persistent AdV infection of lymphocytes. More specifically, this work focuses
on the transcriptional repression of the viral genome that is present during persistent infection and
the roles that cellular transcriptional repressors Class I, II, and III HDACs and the CtBPs play in
repressing AdV genes. This work further focuses on how the CtBPs might link viral gene
expression to the metabolic state of the lymphocyte, as vast metabolic changes are a defining
characteristic of this cell type. The findings presented within this dissertation are the first studies
that have characterized the contribution of these proteins in the persistent AdV infection of
lymphocytes and provide novel insight into cellular requirements for establishment of the
persistent infection and possible mechanisms for reactivation.
In Chapter 2, we demonstrated that in persistently-infected lymphocytic cell lines
transcription of viral genes is repressed compared to lytically-infected cells with similar levels of
viral DNA (Figure 2-1A and B). Our studies focused on viral immediate early gene E1A, early
gene E3, and late gene hexon as representative viral genes expressed at key points in the viral life
cycle, and we were surprised to find that the relative proportions of those transcripts were
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maintained between persistent and lytic infection (Figure 2-1C). However, a more complete
analysis of the viral transcriptome may give further insight into lymphocyte-specific
transcriptional regulation that might play a role in persistence. Using deep cDNA sequencing,
Zhao et al. (2014) recently confirmed fifty distinct viral mRNAs are produced during lytic
infection, some of which had not previously been identified (3). Several viral genes have been
reported to display alternative patterns of expression when compared to lytic infections, suggesting
specific programs of repression are present in persistent infections of lymphocytes (4-6). It is likely
that expression of additional viral gene products is altered in persistent infection as well, and a
robust screening of the complete viral transcriptome of persistently-infected cells could identify
genes which require altered expression to establish persistence.
In Chapter 3, the roles of Class I, II, and III HDACs in repression of viral genes were
investigated. Inhibition of Class I HDAC enzymatic activity upregulated E3 and hexon in both B
and T cell lines, but increased E1A expression only in the T cell line (Figure 3-3). Inhibition of
Class II enzymatic activity did not induce any upregulation in viral gene expression (Figure 3-4),
but deacetylase function is considered less relevant for Class II HDACs compared to their
constituency in repressor complexes and nuclear-cytoplasmic shuttling (7,8). Although Class I
HDACs were uniformly expressed across our cell line models of infection, Class II HDACs were
not (Figure 3-2). In particular, expression of Class II HDAC7 correlated with repression of AdV
gene expression (Figures 3-2 and 2-1B). HDAC7 is more highly expressed in cells of lymphoid
background and is important to lymphocyte development (9). Studies of infection paired with
shRNA knock-down of HDAC7 in lymphocytes or overexpression of HDAC7 in epithelial cells
could give further insight into a possible role of HDAC7 in repression of AdV gene expression.
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Class III HDACs (sirtuins) were found to be involved in repression of late gene hexon
expression in both B and T cell lines (Figures 3-5 and 3-6). This activity may account for the
reduction in viral titers reported with treatment of sirtuin-activator resveratrol (10). Interestingly,
activation of SIRT1 appears to up-regulate expression of E1A (Figure 3-6). Gupta et al. (2013)
have shown that the E1A promoter is regulated, in part, by retention of viral protein VII; the
presence of protein VII at the E1A promoter and surprisingly H4 acetylation suppressed E1A
expression (11). The H4Ac and resulting repression at the E1A promoter appeared to be incurred
through activity of cellular HAT Tip60. As Tip60 is a target for SIRT1 deacetylation (12), which
results in reduced activity, it is possible that SIRT1 activation may upregulate E1A through
targeting of Tip60. The activity of SIRT1 at the E1A promoter, in both lymphocytes and epithelial
cells, requires additional study to fully identify the mechanisms involved.
In addition to the contribution of Class I, II, and III HDACs toward the transcriptional
repression seen in persistent infection, we have also shown that this repression and reactivation
may be tied to the metabolic state of the lymphocyte. Immunoactivation of tonsillar lymphocytes
has been shown to reactivate latent AdV causing increases in viral gene expression and productive
infection (13). In previous studies, a cocktail of immune cell stimulators was used including PMA,
Ionomycin, IL-2, anti-CD3 and anti-CD28, however, no specific mechanisms for viral gene derepression were determined (13).

In Chapter 2, we confirmed that immunoactivation of

lymphocytic cell lines with PMA/Iono upregulates viral gene expression (Figure 2-2B). Activation
of lymphocytes has been shown to shift concentrations of NAD+, its reduced form NADH, and
other key intermediary metabolites, many-fold to meet demands of biosynthetic pathways for
differentiation and proliferation (14-20). The NAD+/NADH ratios of the lymphocytic cell lines
similarly increase in response to PMA/Iono activation (Figure 2-3A), and increasing the
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NAD+/NADH ratio directly through nicotinamide treatment did increase viral gene expression as
well (Figure 2-4B). Thus, our data support the notion that changes in the metabolic status of
lymphocytes can promote reactivation of AdV gene expression.
Understanding how the NAD+/NADH ratio is mechanistically tied to viral gene expression
will require additional work. NAD+ is used as a co-substrate for a number of enzymes including
poly(ADP-ribose) polymerases (PARPs), sirtuins, and cyclic ADP-ribose synthases (cADPRSs)
(21). We have shown that NAD+-dependent sirtuins are involved in the transcriptional repression
of the viral genome in lymphocytes (Figures 3-6 and 3-7), but the involvement of other NAD+dependent enzymes in the regulation of viral gene expression during either lytic or persistent
infection is incompletely understood or has yet to be studied. One of the only other NAD+dependent enzymes to have been studied in lytic infection is DNA-dependent PARP1; the AdV
E4orf4 protein has been found to increase production of viral progeny through inhibition of
PARP1, which is activated by the infection-induced DNA damage response (DDR) (22). E4orf4
inhibition of PARP1 activity was speculated to prevent PARP1-induced depletion of NAD+ and
the resulting necrotic death, although whether AdV infection induces death by this pathway has
not been established (22). However, PARP-induced synthesis and attachment of long poly(ADPribose) chains to proteins has been shown to regulate cellular transcription through chromatin
remodeling and modification of transcription factors (23,24). Studying PARP activity, its
interaction with E4orf4, and shifts to the NAD+/NADH ratio in the context of persistent infection
may provide further insight into how viral transcription is linked to activation of immune cells.
We have also shown that the NAD+/NADH ratio appears to be reduced in persistentlyinfected lymphocyte cell lines, although statistical significance was not reached (Figure 2-3B).
This is the first study suggesting that persistent AdV infection may sustainably alter the
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metabolism of the host cell. In the course of lytic infection cellular metabolism is necessarily
altered to produce metabolic precursors. AdV E4orf1 and E4orf6 proteins bind to MYC and E4orf4
activates the mTOR pathways to activate transcription of genes important for increased glycolysis,
ribose synthesis, and protein synthesis (25,26). How persistent AdV infection could
mechanistically modulate cellular metabolism is unclear. Latent infections of other DNA viruses
have been shown to alter cellular metabolism. KSHV expresses virally-encoded miRNAs, which
increase the rate of glycolysis and fatty acid synthesis, an effect shown to prevent apoptosis of
latently-infected cells (27,28). EBV infection also increases the rate of glycolysis to avoid cell
death in latently-infected cells, an effect modulated by the viral latent membrane protein 1 (LMP1) protein (29). Persistent adenovirus infection of B-lymphocytes has been shown to significantly
down-regulate several cellular genes [BBS9, BNIP3, BTG3, CXADR, SLFN11, and SPARCL (30)],
however, none are reported to obviously function in the regulation of metabolism. It is possible
that some of the other genes identified as altered by AdV infection, such as dual specificity
phosphatase 1 (DUSP1), protein tyrosine phosphatase non-receptor 12 (PTPN12), and
serine/threonine kinase 4 (STK4), which all function in mitogen-activated protein kinase (MAPK)
signaling, could play a role in this effect [(30), supplemental data therein]. MAPK signaling links
environmental stimuli to several metabolic processes, but whether this pathway is involved in
metabolic changes caused by AdV infection remains to be determined. Characterizing the full
repertoire of viral gene products expressed during the persistent AdV infection will be an important
step towards identifying any viral regulators of cellular metabolism important for establishment or
maintenance of persistence.
The role of the NAD-dependent CtBP-E1A interaction in the lytic AdV life cycle is
complex and has been reported to be either repressive or faciliatory, depending on the context. Our
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experiments using the small molecule inhibitor NSC95397 to disrupt CtBP complexes suggest that
CtBP1, which is the only CtBP homolog detectable in our lymphocytic cell lines (Figure 2-5A),
may play a previously unidentified role in repression of E1A in the persistent infection of T cells
while potentiating hexon expression (Figure 2-6, A-C). CtBP repressor complexes contain many
different chromatin modulators including Class I and II HDACs, histone methyltransferases, E3
ligases and other transcriptional regulators which target cellular promoters (31-34). Whether CtBP
repressor complexes occupy the E1A promoter in persistent infection needs to be directly
determined. Additionally, it is currently unclear if persistently-infected lymphocytes express either
the E1A-289R or the -243R proteins, despite detectable levels of mRNAs, because of high levels
of non-specific binding of currently available E1A antibodies (Figure 4-4). A recent study of E1A
13S and 12S mRNAs in single cells revealed that the 13S splice variant was favored in cells
containing lower numbers of viral genomes (4). Both E1A-289R and E1A-243R interact with
CtBP, however, the CR3 region is present only in the longer E1A isoform. This region offers
interaction with different and additional binding partners, so it seems likely that the composition
of CtBP complexes could be different depending on which E1A protein was more highly expressed
in the infected host cell. Pull-down and chromatin immunoprecipitation assays to analyze CtBP1
complex composition and promoter occupancy in persistently-infected lymphocytes could give
further insight into how CtBP1 may be functioning in viral gene repression.
Finally, the experiments examining viral gene expression through the analysis of E1A, E3,
and hexon have revealed that the E1A promoter is responsive to different stimuli in persistentlyinfected lymphocytes than the E3 and major late promoters (Figures 2-2B, 2-4B, 2-6B and C, 3-4,
3-6, 3-7). This is not entirely unexpected, as these promoters contain different known regulatory
elements (Table 1-2). The structure of the different promoters must necessarily be intricately tied
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to the optimal temporal regulation of viral transcription. However, with the exception of the E3
promoter (35), study of the AdV promoters has been done almost entirely in the context of lytic
infection of epithelial cells. Yet, the AdV genome and the regulatory elements therein must have
evolved to optimize both the lytic infection and the persistent infection, the later being the key
phase of the viral life cycle keeping the virus circulating in the population. Because immediate
early gene E1A is critical for both activating other viral genes and for preparing the host cell for
viral replication, the regulation of E1A needs to be considered and investigated from the
perspective of both lytic and persistent infection. E1A must be carefully regulated in cells that do
not progress towards lysis, and chromatinization of the E1A promoter may be important for longterm infection and for potentiating reactivation. Future studies of persistent AdV infection of
lymphocytes should focus on characterizing the state of the viral chromatin at the E1A promoter.
In conclusion, this doctoral work has contributed to the knowledge of mechanisms
regulating transcriptional repression of the AdV genome in persistently-infected lymphocytes.
Clearly, many unanswered questions remain, and no doubt this field will continue to be an exciting
area of research, with many novel mechanisms waiting to be discovered that have allowed this
virus to maintain both its well-known lytic infection and its more enigmatic persistent infection.
Understanding the mechanisms for adenoviral persistence and reactivation may provide novel
targets for therapies to prevent reactivation and disseminated adenoviral infection in pediatric
HSCT recipients.
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APPENDICES
Cell viability and density with different treatment drugs
For the appendices A-E, cells were plated a density of 3 X 105 cells/mL and density and
viability determined at times indicated using Trypan blue exclusion. All experiments were run in
triplicate. Error bars show standard deviation. Concentrations indicated on individual graphs.
Appendix A – Nicotinamide treatment

BJAB - 24 Hours NAM, n = 3

Bar Graph: Cell Density, Line Graph: Viability
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Appendix B – Trichostatin A (TSA) treatment
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Appendix C – Tacedinaline treatment
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Appendix D – TMP195 treatment
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Appendix E – NSC95397 treatment
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Appendix F – Tubacin treatment
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Appendix G – Resveratrol treatment
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Appendix H – Sirtinol treatment
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